Polyphenol Inhibition of Human Pancreatic Lipase: An In-Silico Study Towards Obesity Control

Polyphenol Inhibition of Human Pancreatic Lipase: An In-Silico Study Towards Obesity Control | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Polyphenol Inhibition of Human Pancreatic Lipase: An In-Silico Study Towards Obesity Control Siddha Raj Upadhyaya, Jyoti Bashyal, Bimal Kumar Raut, Niranjan Parajuli This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5360869/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Inhibiting human pancreatic lipase (EC3.1.1.3), a key enzyme in dietary fat breakdown and absorption, is an effective therapeutic approach for obesity control. Polyphenols, due to their multifaceted structure, enhance insulin sensitivity, reduce inflammation, and modulate gut microbiota, offering synergistic effects in controlling obesity. Methods: Considering the adverse side effects associated with current anti-obesity therapeutics, we explored a library of polyphenols known for their antiobesity properties to explicitly potent HPL inhibitors through extensive in-silico study including molecular docking, DFT, MD simulation, PCA, DCCM-based conformational analysis and pharmacokinetic analysis. Results: Significant binding affinity and interactions with catalytic triad (SER 152, HIS 263, and ASP 176) of HPL through molecular docking, alongside higher MM/GBSA values of -53.29, -52.76, and -53.37 kcal/mol, identified (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate), respectively, as potent leads. The DFT study and molecular dynamics simulation affirmed the strong reactivity of these compounds in the catalytic site of HPL and stable protein-ligand complex over 100 ns. FEL, PCA, and DCCM analysis also demonstrated these protein-ligand complexes' stable dynamic behavior and conformational changes. Moreover, post-simulation MMPBSA analysis indicated higher binding free energy and favorable ADMET and drug-likeness pharmacokinetic properties asserted these lead potentials as explicit HPL inhibitors with potential for obesity control. Conclusion: To sum up, (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) are identified as promising HPL inhibitors, with potential application in managing obesity due to their stable interaction with the enzyme and favorable pharmacokinetic characteristics. Computational Biology HPL secondary metabolites molecular docking MD simulations DFT Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 Figure 10 1. Introduction Human pancreatic lipase (triacylglycerol acyl hydrolase EC3.1.1.3), secreted by the acinar cells of the pancreas, exhibits a strong preference for triacylglycerides and collaborates with bile salts in the gastrointestinal tract to hydrolyze them into fatty acids and glycerol [ 1 , 2 ]. HPL is pivotal in regulating lipid metabolism by hydrolyzing 50–70% of dietary fat [ 3 ] essential for lipid absorption. Inhibiting HPL effectively reduces triglyceride intake, offering a potential therapeutic strategy for obesity [ 4 ]—a chronic medical condition characterized by excess adiposity, which affects approximately 650 million individuals globally. Lifestyle interventions, encompassing dietary adjustments, physical activity, and behavioral modifications, entail the primary approach to managing obesity [ 5 ]. Despite their implementation, these interventions typically yield an average weight loss of ~ 10%. Maintaining this weight loss is challenging, with about 80% of the weight normally regained within five years [ 6 ]. Moreover, Obesity is linked with a spectrum of negative health consequences, encompassing metabolic disorders such as stroke, diabetes, atherosclerosis, cardiovascular diseases, hyperlipidemia, hypertension, chronic kidney disease, nonalcoholic fatty liver disease, and cancer alongside depression and osteoarthritis [ 7 , 8 ]. Its profound impact on health necessitates effective preventive and therapeutic interventions. Orlistat, the primary FDA-approved lipase inhibitor for managing obesity, functions by covalently binding to the active serine site of lipases, thereby inhibiting their ability to hydrolyze dietary fat. However, its use leads to gastrointestinal side effects and potential reductions in the absorption of fat-soluble vitamins [ 9 ]. Despite these drawbacks, it is chosen as a standard compound in obesity studies due to its unique mechanism and established efficacy, providing a reliable baseline for evaluating new treatments while ongoing research aims to develop alternatives that minimize side effects, improve patient adherence, and offer full health benefits. Human pancreatic lipase, located at10Q26 of the human chromosome [ 10 ] is composed of 449 amino acids, with SER 152, HIS 263, and ASP 176 forming the conserved catalytic triad [ 11 ]. Its activity relies on the presence of colipase, and lipase inhibitors have shown efficacy in both preclinical and clinical obesity models [ 12 ]. Modulating the activity of human pancreatic lipase may offer new therapeutic approaches to inhibit fat absorption in the body, potentially aiding in treating obesity and associated metabolic disorders [ 13 ]. Natural products have high safety profiles, effectively inhibit pancreatic lipase, and have significant gastrointestinal exposure, making them advantageous in treating metabolic disorders associated with obesity( X.-D. Hou et al., 2022). Phytochemicals offer a promising alternative to current medication, addressing major issues related to gut microbiota and nutrient deficiencies, underscoring the necessity of managing side effects while targeting specific enzymes [ 15 , 16 ]. Key pharmacological actions that aid in obesity control include their effects on lipid metabolism and adipogenesis [ 17 ]. Polyphenols, in particular, demonstrate modest effects through multiple metabolic targets and pathways, such as suppression of food intake, inhibition of lipogenesis, enhancement of lipolysis, prevention of fatty acid oxidation, and inhibition of adipogenesis and apoptosis [ 18 , 19 ]. The chemical structure, substitutions, and number of hydroxyl groups in polyphenols significantly affect their bioavailability and absorption. Consequently, these factors have a major influence on their biological activities, including their antioxidant characteristics, free radical scavenging, enhanced insulin sensitivity, reduced inflammation, and modulation of gut microbiota, providing synergistic benefits for obesity control [ 20 ]. Breakthroughs in pharmaceutical sciences, like computer-aided screening (CAS), molecular docking, molecular dynamics (MD) simulations, and computer-aided drug design (CADD), are key to rapidly discovering potent drug compounds and refining methodologies in drug discovery and development [ 21 , 22 ]. To explore potential new target sites, we developed a robust computational framework that encompasses docking, molecular mechanics using generalized Born and surface area solvation (MM/GBSA), molecular dynamics (MD) simulations, density functional theory (DFT), along with pharmacokinetic and toxicity assessments. This framework focuses on predicting the effectiveness of polyphenols as inhibitors of HPL. It emphasizes inhibitors that demonstrate strong binding affinities and maintain stable interaction poses with the catalytic sites. The analysis includes key stability indicators like root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), the radius of gyration (Rg), solvent-accessible surface area (SASA), and hydrogen bond interactions. These inhibitors are expected to bind efficiently to the target enzyme, exhibiting potent reactivity and kinetic stability, thereby effectively suppressing obesity. 2. Materials and Methods 2.1 Library of Compounds and Ligand Preparation A library of polyphenols, recognized for their reported in vitro antiobesity properties, was prepared to identify potential HPL inhibitors in context to their therapeutic purposes. The library of included metabolites in the library are presented in Table S1 and Figure S1 . The 3D conformer of each ligand sourced from the PubChem database ( https://pubchem.ncbi.nlm.nih.gov/ ) was imported into the Flare workspace through their canonical SMILES. Utilizing a ligand prep module, each ligand was prepared by minimizing energy while maintaining a pH of 7. 2.2 Protein preparation and validation A lipase protein (PDB ID: 1LPB), with no mutation and 2.46 Å resolution, was retrieved from the protein data bank ( https://www.rcsb.org/ ) and imported into the Flare workspace using the input protonation state. The protein prep module was then employed to prepare protein by; removing complexed ligands, capping residues, maintaining a pH of 7, allowing slight side chain movements, eliminating atoms from residues with incomplete backbones, discarding water molecules and unwanted chains, and filling gaps in residues. 2.3 Molecular Docking Utilizing Cresset Flare Flare Pro + software ( http://www.cresset-group.com/flare/ ) [ 23 ], a molecular docking study of selected metabolites was performed. The grid size was created by enclosing the catalytic triad residues. The docking calculation was performed in normal mode, with the evaluation of the results based on their interaction and binding affinity. Lead Finder™, which features a specific algorithm and scoring functions for virtual screening, was applied in docking analysis. Validation of the procedure was achieved through redocking and superimposition, ensuring reliable and consistent outcomes [ 24 ]. 2.4 MM/GBSA binding energy calculations The MM/GBSA calculations were performed for the docked protein-ligand complex utilizing Cresset Flare Pro + software in normal mode with the default settings ( https://www.cresset-group.com/flare ) [ 25 ]. 2.5 Electrostatic complementarity An electrostatic complementarity analysis was carried out with the Flare Pro + module of Cresset software to assess the electrostatic compatibility between the selected ligands and the protein binding pocket [ 26 ]. Non-covalent interactions between small molecules and their receptors significantly impact the binding affinity of the protein-ligand complex. This evaluation provides details regarding the binding interactions of these ligands with the HPL targets. 2.6 Density Functional Theory (DFT) DFT analysis utilizing GuassView 6 and Guassian 09 software ([ 27 ] with the Becke, 3-parameter, Lee-Yang-Parr (B3LYP) functional and the 6-31G (d,p) basis set was performed to assess the reactivity of listed phytochemicals and orlistat within the protein's catalytic domain [ 28 ]. The band gap energy (ΔE) was calculated by computing the energies of the frontier molecular orbitals, specifically the highest occupied (E HOMO ) and lowest unoccupied molecular orbital (E LUMO ) [ 29 , 30 ]. The formulae below were used to compute the ionization potential (I), electron affinity (A), chemical hardness (η), chemical softness (S), electronegativity (χ), electrophilicity index (⍵), and chemical potential (µ) [ 29 – 31 ]. Energy difference of HOMO and LUMO (ΔE gap ) = E LUMO − E HOMO ……………..(Eq. 1) Ionization potential (I) = − E HOMO ……....................................................................(Eq. 2) Electron affinity (A) = − E LUMO ……………………………………………………(Eq. 3) Chemical (Global) hardness (η) = ΔE/2 ……………………………………….…..(Eq. 4) Chemical softness (S) = 1/η ………………………………………………………..(Eq. 5) Electronegativity (χ) = (I + A) / 2 ≈ − µ (chemical potential) ………………..……(Eq. 6) Electrophilicity index (ω) = µ 2 /2η ……………………………………………...….(Eq. 7) 2.7 Molecular Dynamics Simulation A 100 ns molecular dynamics (MD) simulation was performed using Gromacs software to evaluate the conformational dynamics and stability of the biomolecules [ 32 , 33 ]. MD simulation focused on complexes with binding affinities < − 9.0 kcal/mol. The ligand topology file was initially developed using the Swissparam website [ 34 ], while protein topology files were created using the CHARMM27 force field with a simple point charge (SPC) water model. Then the protein.gro and ligand.gro files were combined to create the complex.gro files. The complex was enclosed in a triclinic box under periodic boundary conditions and neutralized with Cl − or Na + ions. The steepest descent algorithm was employed to perform energy minimization for 5,000 steps. The system was then equilibrated under NVT conditions at 300 k temperature for 50,000 steps, followed by NTP conditions at 1 atm pressure for 50,000 steps (100 ps). The last step was to run a 100 ns MD simulation. The simulation results were analyzed using RMSD, RMSF, Rg, SASA, hydrogen bonding, and the free energy landscape (FEL) [ 35 ]. 2.8 Principal Component Analysis (PCA) and Dynamic Cross-Correlation Matrix (DCCM) Analysis Principal component analysis (PCA) was used using the Bio3d package in R Studio to evaluate the dynamic behavior and conformational space of biomolecules [ 36 ]. The analysis involved evaluating the eigenvectors and eigenvalues, as well as their projections onto the initial three principal components [ 37 ]. The variable dynamic behavior of complexes essential for biological activities was extracted through PCA [ 38 ]. It was expected that stable protein-ligand complexes would exhibit reduced dynamic fluctuations due to the increased rigidity of the ligand-binding sites. Additionally, dynamic cross-correlation matrix (DCCM) analysis was conducted utilizing the Bio3D package [ 36 ] to understand and compare the dynamic and conformational changes occurring in apo-protein and protein-ligand complexes. 2.9 Molecular Mechanics Poisson-Boltzman Surface Area (MM/PBSA) Protein-ligand complex binding energies, which are necessary for MD simulations and thermodynamic assessments, were assessed using the gmx_MMPBSA module of the GROMACS software. The binding energy (ΔGbind) of protein and ligand complexes was determined using the well-known MM-PBSA technique in conjunction with MD simulations, as shown by the equation [ 39 ]: ΔG bind = G complex - (G receptor + G ligand ) 2.10 Pharmacokinetic Analysis The physicochemical properties of the compounds were evaluated using the SwissADME drug-likeness online platform [ 40 ]. Likewise, the ADMET and toxicity profile were accessed using pkCSM [ 41 ] and ProTox-II web servers [ 42 ], respectively. 3. Results and Discussions 3.1 Molecular Docking and MM/GBSA Calculation Molecular docking, a key approach in drug discovery, advances the prediction of enzyme inhibitors by offering a detailed insight into their interactions and effectiveness [ 43 ]. Initially, the chosen polyphenols were evaluated through molecular docking, which involved analyzing binding scores and competitive interactions with catalytic residues to determine the most effective HPA inhibitor. To ensure the accuracy and reliability of the molecular docking process, redocking was performed, showing an RMSD value of under 2 Å for the ligand [ 44 ]. After successful validation, the selected compound library was docked into the catalytic diad of HPL, and the results were analyzed regarding interaction with the active site, binding affinity, and MM/GBSA value. Docking results were expressed as LF (LigandFit) rank score, LF dG score, LF Vscore, and LF LE (LigandFit Ligand Efficiency) score. LF rank and dG here signify the exact ranking of each docked ligand pose by energy and the binding affinity, respectively, while VSscore and LE illustrate the correct ranking of compounds as active or inactive in virtual screening and the estimated efficiency of the ligand [ 45 ]. These compounds showed LF Rank scores ranging from − 2.255 to -11.09, LF dG score from − 0.462 to -19.516, LF Vscore from − 4.377 to -12.689, LF LE score from − 0.015 to -0.61, and MM/GBSA from − 24.47 to -53.37 kcal/mol, compared to reference ligand orlistat, which exhibited an LF Rank score of 0.293, an LF dG of -8.343, an LF Vscore of -8.864, an LF LE of -0.238, and an MM/GBSA of -49.4 kcal/mol. Using MM/GBSA, which provides a prominent binding score [ 46 ], three compounds—(-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate)—exhibited higher MM/GBSA of -53.29, -52.76, and − 53.37 kcal/mol, respectively, compared to orlistat (-49.4 kcal/mol). Their interactions with catalytic residues, as detailed in Table S2 , underscore their significance in inhibiting HPL. (-)-epigallocatechin-3-O-p-coumarate showed hydrogen bonds interaction with SER 152 (Fig. 1 A and Table 1 ), a catalytic residue accountable for the hydrolysis of triglycerides into smaller absorbable forms, thereby managing obesity. The active site residues SER 152 and HIS 263 formed strong hydrogen bonds with (+)-catechin-3-O-gallate (Fig. 1 B). Similarly, (-)-epicatchein-3-O-(3'-O-methyl gallate) exhibited catalytic inhibition via hydrogen bonds with SER 152 (Fig. 1 C). These compounds demonstrated potency for competitive inhibition through interactions with catalytic site residues and higher MM/GBSA values (Table 1 ), indicating a need for further investigation with additional in-silico analyses. Table 1 Molecular docking and MM/GBSA results Compound LF Rank score LF dG LF Vscore LF LE Interactions MM/GBSA (-)-Epigallocatechin-3-O-p-coumarate -5.601 -8.13 -9.928 -0.246 H-bond: GLY76, ASP79, TYR114, HIS151, SER152 Aromatic-Aromatic: TYR114 Cation-pi: HIS263 -53.29 (+)-catechin-3-O-gallate -10.381 -10.166 -10.821 -0.318 H-bond: GLY76, PHE77, ASP79, TYR114, SER152, PHE215, HIS263 Aromatic-Aromatic: PHE77, HIS151, PHE215, HIS263 -52.76 (-)-Epicatechin-3-O-(3'-O-methyl gallate) -10.377 -10.751 -11.617 -0.326 H-bond: GLY76, ASP79, HIS151, SER152, PHE215, ARG256, HIS263 Aromatic-Aromatic: PHE215, and HIS263 -53.37 Orlistat 0.293 -8.343 -8.864 -0.238 H-bond: PHE77, SER152, HIS263 -49.4 3.2 Electrostatic complementarity The three screened ligands—(-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) were subjected for electrostatic complementarity analysis in context to EC, EC r and EC rho. EC is a normalized complementarity score surface integral that effectively provides the average score throughout the surface of the ligand, while EC r and EC rho represent the Spearman rank correlation coefficient and Pearson's correlation coefficient, respectively. The electrostatic potential of proteins and ligands sampled on the surface vertices is often computed using these scores [ 45 ]. These scores' metrics vary, but they often fall between 1 (perfect complementarity) and − 1 (complete clash). As shown in Table 2 , all three ligands were found to manifest better electrostatic complementarity scores with no indication of steric clashes, thereby indicating their potential for HPL inhibition. Table 2 Electrostatic complementarity results of (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate). Compounds EC EC r EC rho (-)-Epigallocatechin-3-O-p-coumarate 0.198 0.118 0.128 (+)-catechin-3-O-gallate 0.192 0.097 0.057 (-)-Epicatechin-3-O-(3'-O-methyl gallate) 0.23 0.17 0.081 3.3 DFT The reactivity of ligands in catalytic site of HPL was evaluated using a DFT study. The band-gap energy, which is the difference between the LUMO and HOMO energies (E LUMO − E HOMO ), serves as an indicator of molecular reactivity. Ligands with a smaller band-gap energy are more polarizable and exhibit higher chemical reactivity [ 47 ]. As displayed in Fig. 2 , the hit compounds showed higher reactivity with lower band gap energy compared to the reference compound orlistat. Furthermore, their ionization energy and electron affinity indicate greater reactivity, indicating their capabilities to donate and attract electrons [ 48 ]. To better comprehend the protein-ligand interaction and the effectiveness of the drug, quantum mechanical parameters of chemical hardness (η), softness (S), electronegativity (χ), electrophilic index (ω), and chemical potential (µ) play crucial roles. These parameters characterize the ligand's reactivity and chemical stability. The χ indicates a molecule's ability to attract electrons, η, and S denotes the presence of barriers to electron flow, ω represents the energy lost as a result of the electrons flowing between them, and µ marks the electron transfer path [ 49 – 51 ]. When compared to the orlistat, all of the previously described metrics, as displayed in Table S3 , the hit compounds showed excellent efficacy of reactivity in the binding pocket of HPL. 3.4 Molecular Dynamic Simulation In computational-aided drug design (CADD), MD simulations are pivotal by revealing complex molecular behaviors at atomic and molecular levels. They also contribute to a deeper understanding of protein or enzyme interactions with drug targets, thereby facilitating the optimization of drug candidates [ 52 ]. 3.4.1 Root mean square deviation (RMSD) Through RMSD analysis, dynamic behaviors were explored, uncovering shifts in conformation and structural modifications in the backbone of both apoprotein and protein-ligand complexes [ 53 ]. Additionally, it facilitates the comparison of the native folded protein structure with its partly or completely unfolded counterparts, serving as a valuable reaction coordinate in protein folding studies [ 54 ]. The RMSD plot of all complexes is displayed in Fig. 3 . The RMSD graph revealed that all selected complexes along with apo-proprotein gain remarkable stability within a 20 ns simulation trajectory. Although the RMSD value of the orlistat complex is lower than that of the selected candidates, it achieves stability only after 60 ns of simulation trajectory. The apo-protein has the lowest RMSD value with an average of 0.18 nm, followed by the orlistat-protein complex with an average of 0.24 nm. The (-)-epigallocatechin-3-O-p-coumarate complex has an average RMSD value of 0.33 nm, (+)-catechin-3-O-gallate has 0.36 nm, and (-)-epicatechin-3-O-(3’-O-methyl gallate) complex has 0.41 nm. The average RMSD values for each complex, including the apo-protein, are presented in Table 3 . Table 3 MD simulation results spanning 100 ns for (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) Complex Average RMSD (nm) Average RMSF (nm) Average Rg (nm) Average SASA (nm 2 ) (+)-Catechin-3-O-gallate 0.36 0.13 2.63 238.99 (-)-Epigallocatechin-3-O-p-coumarate 0.33 0.14 2.63 237.49 (-)-Epicatechin-3-O-(3’-O-methyl gallate) 0.41 0.13 2.65 236.50 Apo-protein 0.18 0.11 2.59 234.54 Orlistat (reference) 0.24 0.09 2.62 237.09 3.4.2 Root mean square fluctuations (RMSF) RMSF assesses the displacement of particular atoms or groups of atoms from the reference structure, averaged across all atoms. It is employed to investigate the dynamic behavior of specific amino acids within the protein-ligand complexes' backbone. Higher RMSF values suggest increased flexibility and mobility in specific protein regions, providing insights into the characteristics of protein loops and protease-labile segments [ 55 ]. Likewise, secondary protein structures like helices and sheets are stable when their RMSF value is lower. All complexes along with the apo-protein exhibited fluctuations in similar regions. The current study revealed orlistat complex showed the lowest fluctuations with an average fluctuation of 0.09 nm, followed by apo-protein with an average RMSF of 0.11 nm, (+)-catechin-3-O-gallate complex and (-)-epicatechin-3-O-(3’-O-methyl gallate) complex have an average RMSF of 0.13 nm (Table 3 ). In addition, (-)-epigallocatechin-3-O-p-coumarate complex exhibited the highest RMSF with an average of 0.14 nm. Figure 4 shows that high levels of fluctuation were observed in VAL210, PRO211, ASN240 to THR255, GLN233, GLY348 to HIS354, LYS 363, THR375 to ASP379, and TYR403 to ARG414 amino acid residues, none of which are part of the catalytic site. 3.4.3 Radius of gyration (Rg) The stability of the selected complexes and apo-protein was evaluated using the radius of gyration (Rg). This measure was analyzed over a 100 ns simulation trajectory to assess the structural compactness, stability, and conformational states of the complexes and the apo-protein [ 56 ]. The MD simulation results showed that all protein-ligand complexes exhibited Rg values nearly comparable to those of the apo-protein, indicating all ligands bind effectively in the binding pocket of the protein. (+)-catechin-3-O-gallate-protein and (-)-epicatechin-3-O-p-coumarate-protein complexes exhibited equal Rg value of 2.63 nm, suggesting both complexes have comparable stability. The (-)-epicatechin-3-O-(3’-O-methyl gallate)-protein complex displayed the highest average Rg value of 2.65 nm, while the orlistat (reference)-protein complex exhibited a slightly lower average Rg value of 2.61 nm (Table 3 ). The Rg values obtained during the 100 ns simulation trajectory indicate that all the protein-ligand complexes achieved a relatively stable folded conformation. In summary, the Rg graph (Fig. 5 ) demonstrated that all the selected compounds, along with the reference, bind effectively with the protein and form more compact structures. 3.4.4 Solvent accessible surface area (SASA) The solvent-accessible surface area (SASA) parameter quantifies the area of the protein and protein-ligand complex that is exposed to organic solvents and water. SASA is crucial for assessing the extent of conformational changes during interactions. Typically, the bound conformation of biomolecules exhibits a higher SASA value in comparison to their unbound state [ 57 ]. A lower SASA value suggests a more compact structure with less surface area available for solvent interactions. The apo-protein, in its unbound conformation, has the lowest SASA value, averaging 234.54 nm², while the protein-ligand complexes have slightly higher SASA values. The (-)-epicatechin-3-O-(3’-O-methyl gallate) complex has the lowest average SASA value compared to the other protein-ligand complex (Fig. 6 ), suggesting (-)-epicatechin-3-O-(3’-O-methyl gallate) bind strongly in the binding pocket of the protein, making the complex more compact. Similarly, orlistat complex has an average SASA value of 237.09 nm 2 , (+)-catechin-3-O-gallate complex has an average of 238.99 nm 2 , and (-)-epicatechin-3-O-p-coumarate complex has 237.49 nm 2 (Table 3 ) . Overall, all the protein-ligand complexes have lower SASA values, which suggests all the ligands bind effectively in the binding site of the protein and make the complex more compact. 3.4.5 Hydrogen bonding Given the importance of hydrogen bonds in ligand binding and their influence on biological functions like as metabolism, adsorption, drug affinity, and specificity, analyzing hydrogen-bonding patterns during the MD simulation is crucial. Assessing hydrogen bond interactions is a key step in elucidating and characterizing the molecular interaction patterns of protein-ligand complexes through molecular dynamics simulations [ 58 , 59 ]. In the current investigation, we analyzed hydrogen bonds from MD trajectory to assess the stability between lipase and the potent ligands. It was observed that all the complexes constantly retained hydrogen bonds across the 100 ns simulation trajectory, as shown in Fig. 7 . (-)-epigallocatechin-3-O-p-coumarate and (-)-epicatechin-3-O-(3’-O-methyl gallate) complex exhibited the highest of five hydrogen bonds during 100 ns simulation trajectory. The Orlistat complex was found to have up to four hydrogen bonds and the (+)-catechin-3-O-gallate complex exhibited a maximum of two hydrogen bonds. These hydrogen-bond observations revealed that all ligands were effectively and securely bound to the enzymes through hydrogen bonding. 3.5 Free energy landscape Proper folding and confirmation are crucial for biomolecules to function correctly. FEL aids in evaluating the conformational variability and free energy of protein structures. Conformational diversity assesses how diverse the sampled conformations are, while the free energy parameter provides insight into their relative stability and accessibility [ 60 , 61 ]. These insights into conformational dynamics provide valuable perspectives for understanding protein biological functions and guiding the development of inhibitors or drugs [ 62 ]. The Gibbs free energy landscape was determined utilizing gmx_covar , gmx_anaeig , and gmx_sham , based on the projections of their first (PC1) and second (PC2) eigenvectors, respectively. In the FEL plot, a red spot indicates a folded macromolecular structure with low Gibbs free energy, whereas a blue spot signifies an unfolded structure with high Gibbs free energy [ 63 ]. A yellow spot denotes intermediate energy, while green represents the metastable frame duration of biomolecules. The figure of Gibbs free energy is displayed in Fig. 8 . As shown in Fig. 8 (B), lipase gained a more folded structure after forming a complex with (-)-epigallocatechin-3-O-p-coumarate, while orlistat-lipase resulted in an unfolded structure. Overall, all three selected ligands gained folded structure after binding with protein. In conclusion, the free energy landscape plot, which reflects conformational changes, demonstrated the overall stability of biomolecules when complexed with (+)-catechin-3-O-gallate, (-)-epigallocatechin-3-O-p-coumarate, (-)-epicatechin-3-O-(3’-O-methyl gallate), and orlistat. 3.6 Principal component analysis (PCA) and dynamic cross-correlation matrix (DCCM) analysis Principal component analysis (PCA) was conducted on the Cα atoms for both the apo-protein and the protein-ligand complex trajectories. PCA revealed the initial seven eigenvectors of apo-protein as well as (+)-catechin-3-O-gallate and (-)-epigallocatechin-3-O-p-coumarate complexes accounted more than 90% of movement, whereas, (-)-epicatechin-3-O-(3’-O-methyl gallate) complex account around 50% of movement and orlistat (reference) complex accounted only around 38% of movement. (+)-catechin-3-O-gallate and (-)-epigallocatechin-3-O-p-coumarate explored significantly larger conformational space (Fig. 9 ). PCA assessment of the root mean square fluctuation (RMSF) showed heightened fluctuations in the loop region of the apo-protein after ligand binding. This is because loops typically have more fluctuations compared to helices. Such increased fluctuations are indicative of conformational changes in the apo-protein. Comparable flexibility in PC1 and PC2 was observed for (-)-epicatechin-3-O-(3’-O-methyl gallate) when compared to the apo-protein. Whereas, (+)-catechin-3-O-gallate and (-)-epigallocatechin-3-O-p-coumarate exhibited increased flexibility in the binding site of apo-protein, on the other hand, orlistat showed reduced flexibility. Additionally, the evaluation of the dynamic cross-correlation matrix was evaluated using the Cα atom coordinates from the 100 ns molecular dynamics trajectories. The result of the DCCM analysis is displayed in Fig. 10 . The DCCM plot of (-)-epicatechin-3-O-(3’-O-methyl gallate)-complex indicates a slight overall increase in negatively correlated motion upon ligand binding, whereas (+)-catechin-3-O-gallate showed a much greater increase in anti-correlated motion. In contrast, (-)-epigallocatechin-3-O-p-coumarate exhibited overall positively correlated motions. The highest negatively correlated motion was observed for (+)-catechin-3-O-gallate complex. Orlistat (reference) complex showed reduced correlation in motion. In brief, compared to the apo-protein, negatively correlated motions in the binding pocket of protein increase upon the binding of potent ligands. Therefore, it is likely to be concluded that the binding of selected phytochemicals creates a more stable environment compared to the orlistat. 3.7 Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA) The MM/PBSA approach, which combines molecular mechanics with Poisson-Boltzmann surface area continuum solvation, is a utilized method technique for calculating the binding free energy of protein-ligand complexes [ 64 ]. Thus, the MMPBSA analysis combined with MD simulations demonstrated significant differences in the free-binding energies of the studied compounds, as illustrated in Table 4 . Particularly, (+)-catechin-3-O-gallate complex exhibited significant binding energy of -59.46 kcal/mol, (-)-epigallocatechin-3-O-p-coumarate complex unveiled a binding affinity of -56.54 kcal/mol, and the (-)-epicatechin-3-O-(3’-O-methyl gallate) complex demonstrated the binding energy of -48.48 kcal/mol. In contrast, the orlistat complex displayed a comparatively low binding energy of 40.26 kcal/mol. These results highlight the strong binding properties of (+)-catechin-3-O-gallate, (-)-epigallocatechin-3-O-p-coumarate complex, and (-)-epicatechin-3-O-(3’-O-methyl gallate compared to the reference ligand orlistat. Table 4 Free binding energy of protein-ligand complex through MMPBSA Complex ΔG complex (kcal mol − 1 ) ΔG protein (kcal mol − 1 ) ΔG ligand (kcal mol − 1 ) ΔG bind (MM/PBSA) (kcal mol − 1 ) (+)-Catechin-3-O-gallate complex -1604.26 -1639.46 24.26 -59.46 (-)-Epigallocatechin-3-O-p-coumarate complex -1612.72 -1646.54 22.72 -56.54 (-)-Epicatechin-3-O-(3’-O-methyl gallate) complex -1607.28 -1629.64 26.12 -48.48 Orlistat complex -1608.89 -1642.45 6.70 40.26 3.8 In Silico pharmacokinetic study A compound must exhibit high selectivity and minimal adverse effects to be considered a potential drug candidate [ 65 ]. The effectiveness and eventual appearance of side effects attributed mostly to the compound's ADMET properties lead to a high attrition rate in the final phase of drug development [ 66 ]. However, the likelihood of failure for a promising candidate can be reduced by using in-silico techniques. Hence, the drug-likeness and ADMET parameters of the potent candidates, (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate), were thoroughly evaluated and displayed in Table S4 and Table S5 respectively. For a successful drug candidate, solubility is a crucial physicochemical property[ 67 ]. SwissADME’s ESOL, Ali, and SILICOS-IT models, a solubility parameter[ 40 ], predicted (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) as soluble and (-)-epigallocatechin-3-O-p-coumarate as moderate soluble ( Table S4 ). All these three hit compounds surpass the minimal intestinal absorption criteria of 30%. Similarly, these compounds were found to be safer based on blood-brain barrier (BBB) permeability and log VDss, which indicate absorption into the brain that results in neurotoxicity and distribution in the tissues, respectively [ 68 ]. Drug metabolism and the detoxification of foreign substances are greatly aided by cytochrome P450 enzymes, particularly CYP3A4 [ 69 ], the hit compounds don't inhibit CYP3A4, and therefore possess no negative effects and are readily metabolized in the liver. AMES toxicity and hepatotoxicity are crucial factors in assessing drug-induced liver injury and mutagenicity [ 70 ]. The hit compounds showed no AMES toxicity and hepatotoxicity, thereby indicating non–mutagenicity and non-drug-induced liver injury ( Table S5 ). Moreover, the hit compounds were further subjected to drug-likeness Lipinski’s rule and Veber's rule to assess whether the hit compounds have drug-like properties or not. As per the Lipinski's rule of five criteria [ 71 ]—molecular weight ≤ 500 Da, log P ≤ 5, hydrogen bond donors ≤ 5, and hydrogen bond acceptors ≤ 10—and Veber's rule [ 72 ]—TPSA > 140 Ų and rotatable bonds ≤ 10—the hit compounds exhibited better drug-like properties compared to the reference compound, orlistat. The hit compounds—(-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate), therefore, demonstrated favorable pharmacokinetic properties, including significant intestinal absorption, acceptable drug-like behavior, good bioavailability, non-inhibition of cytochrome P450, and minimal toxicity ( Table S6 ). Tea polyphenols have been effective in controlling obesity by inhibiting human pancreatic lipase, thereby reducing fat absorption [ 19 , 73 ]. Our potent compounds through in silico analysis—(+)-catechin-3-O-gallate, (-)-epigallocatechin-3-O-p-coumarate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) found to demonstrate significant in vitro inhibition assay with IC 50 value of 4.57 [ 74 ], 0.835, and 0.68 µM [ 73 ], respectively. These results indicate their potential effectiveness in controlling obesity. 4. Conclusion Encompassing a diverse range of plant species and dietary sources, polyphenols are a heterogeneous group of secondary metabolites that have gained remarkable concentration in the present days for their potential health benefits, especially the ability to control obesity. Our extensive in-silico study on a library of polyphenols has identified (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) as potent inhibitors of HPL. These polyphenols demonstrated significant binding affinity and interactions with the catalytic residues of HPL, supported by high MM/GBSA values. Further validation through DFT studies and MDs simulations in regards to RMSD, RsMSF, Rg, SASA, and H-bonding confirmed the strong reactivity and stability of these compounds in the catalytic region of HPL. Similarly, the FEL plot revealed all selected protein-ligand complexes gained folded conformation, and the PCA and DCCM plots showed stable dynamic behavior of complexes after 100 ns simulation trajectory. Additionally, post-simulation MM/PBSA analysis indicated favorable binding free energy and ADMET and drug-likeness assessments affirmed their potential as effective and safe therapeutic agents for obesity management. These findings indicate that the identified polyphenols could be promising candidates for the development of anti-obesity therapeutics. However, future research should be carried out to experimentally validate these findings through pharmacokinetics studies. Declarations Acknowledgment We would like to acknowledge Cresset-group for providing the license of Flare and Spark software. Funding Statement There was no funding for this research. Conflict of Interest Statement The authors report there are no competing interests to declare. Author contributions S.R.U. performed computational work, analyzed data, and wrote the manuscript; J.B. did a literature review, analyzed data, and drafted the manuscript; B.K.R. performed in silico and drafted the manuscript and N.P. supervised the manuscript. Data Availability Statement The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. Ethical Approval : Ethical approval was not necessary for this computational study since it did not involve animals, human participants, or identifiable data. References Kumar A, Chauhan S (2021) Pancreatic lipase inhibitors: The road voyaged and successes. Life Sci 271:119115 Mukherjee M (2003) Human digestive and metabolic lipases—a brief review. J Mol Catal B: Enzymatic 22:369–376 Whitcomb DC, Lowe ME (2007) Human Pancreatic Digestive Enzymes. Dig Dis Sci 52:1–17 Lowe ME (1994) Pancreatic triglyceride lipase and colipase: Insights into dietary fat digestion. Gastroenterology 107:1524–1536 Melson E, Ashraf U, Papamargaritis D, Davies MJ (2024) What is the pipeline for future medications for obesity? Int J Obes [Internet]. [cited 2024 Aug 6]; https://www.nature.com/articles/s41366-024-01473-y Hall KD, Kahan S (2018) Maintenance of Lost Weight and Long-Term Management of Obesity. Med Clin North Am 102:183–197 Lin X, Li H, Obesity (2021) Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol 12:706978 Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML et al (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:804–814 McClendon KS, Riche DM, Uwaifo GI (2009) Orlistat: current status in clinical therapeutics. Exp Opin Drug Saf 8:727–744 Davis RC, Diep A, Hunziker W, Klisak I, Mohandas T, Schotz MC et al (1991) Assignment of human pancreatic lipase gene (PNLIP) to chromosome 10q24–q26. Genomics 11:1164–1166 Egloff M-P, Marguet F, Buono G, Verger R, Cambillau C, Van Tilbeurgh H (1995) The 2.46.ANG. Resolution Structure of the Pancreatic Lipase-Colipase Complex Inhibited by a C11 Alkyl Phosphonate. Biochemistry 34:2751–2762 Liu T-T, Liu X-T, Chen Q-X, Shi Y (2020) Lipase Inhibitors for Obesity: A Review. Biomed Pharmacother 128:110314 D’Agostino D, Lowe ME (2004) Pancreatic Lipase-related Protein 2 Is the Major Colipase-Dependent Pancreatic Lipase in Suckling Mice. J Nutr 134:132–134 Hou X-D, Qin X-Y, Hou J, Tang H, Ge G-B (2022) The potential of natural sources for pancreatic lipase inhibitors: a solution of the obesity crisis? Expert Opin Drug Discov 17:1295–1298 Hossen I, Hua W, Ting L, Mehmood A, Jingyi S, Duoxia X et al (2020) Phytochemicals and inflammatory bowel disease: a review. Crit Rev Food Sci Nutr 60:1321–1345 Sudheer S, Gangwar P, Usmani Z, Sharma M, Sharma VK, Sana SS et al (2022) Shaping the gut microbiota by bioactive phytochemicals: An emerging approach for the prevention and treatment of human diseases. Biochimie 193:38–63 Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R et al (2014) Novel insights of dietary polyphenols and obesity. J Nutr Biochem 25:1–18 He Q, Lv Y, Yao K (2007) Effects of tea polyphenols on the activities of α-amylase, pepsin, trypsin and lipase. Food Chem 101:1178–1182 Singh M, Thrimawithana T, Shukla R, Adhikari B (2020) Managing obesity through natural polyphenols: A review. Future Foods 1–2:100002 Gasmi A, Mujawdiya PK, Noor S, Lysiuk R, Darmohray R, Piscopo S et al (2022) Polyphenols Metabolic Dis Molecules 27:6280 Azad I, Khan T, Ahmad N, Khan AR, Akhter Y (2023) Updates on Drug Designing Approach Through Computational Strategies: a Review. Future Sci OA 9:FSO862 Roda S, Fernandez-Lopez L, Cañadas R, Santiago G, Ferrer M, Guallar V (2021) Computationally Driven Rational Design of Substrate Promiscuity on Serine Ester Hydrolases. ACS Catal 11:3590–3601 Cheeseright T, Mackey M, Rose S, Vinter A (2006) Molecular Field Extrema as Descriptors of Biological Activity: Definition and Validation. J Chem Inf Model 46:665–676 Elekofehinti OO, Ejelonu OC, Kamdem JP, Akinlosotu OB, Famuti A, Adebowale DD et al (2018) Discovery of potential visfatin activators using in silico docking and ADME predictions as therapy for type 2 diabetes. Beni-Suef Univ J Basic Appl Sci 7:241–249 Kuhn M, Firth-Clark S, Tosco P, Mey ASJS, Mackey M, Michel J (2020) Assessment of Binding Affinity via Alchemical Free-Energy Calculations. J Chem Inf Model 60:3120–3130 Bauer MR, Mackey MD (2019) Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein–Ligand Complexes. J Med Chem 62:3036–3050 Gaussian 09 Citation | Gaussian.com [Internet]. [cited 2024 Aug 16]. https://gaussian.com/g09citation/ Gill PMW, Johnson BG, Pople JA, Frisch MJ (1992) The performance of the Becke—Lee—Yang—Parr (B—LYP) density functional theory with various basis sets. Chem Phys Lett 197:499–505 AL-Ishaq (2019) Abotaleb, Kubatka, Kajo, Büsselberg. Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels. Biomolecules 9:430 Kumar CBP, Raghu MS, Prasad KNN, Chandrasekhar S, Jayanna BK, Alharthi FA et al (2021) Investigation of biological activity of 2,3-disubstituted quinazolin-4(1 H )-ones against Mycobacterium tuberculosis and DNA via docking, spectroscopy and DFT studies. New J Chem 45:403–414 Oyewole RO, Oyebamiji AK, Semire B (2020) Theoretical calculations of molecular descriptors for anticancer activities of 1, 2, 3-triazole-pyrimidine derivatives against gastric cancer cell line (MGC-803): DFT, QSAR and docking approaches. Heliyon 6:e03926 Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B et al (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2:19–25 Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R et al (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29:845–854 Zoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: A fast force field generation tool for small organic molecules. J Comput Chem 32:2359–2368 Abraham M, Alekseenko A, Bergh C, Blau C, Briand E, Doijade M et al (2023) GROMACS 2023 Manual. [cited 2024 Aug 6]; https://zenodo.org/record/7588711 Grant BJ, Rodrigues APC, ElSawy KM, McCammon JA, Caves LSD (2006) Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22:2695–2696 Al-Khafaji K, Taskin Tok T (2021) Amygdalin as multi-target anticancer drug against targets of cell division cycle: double docking and molecular dynamics simulation. J Biomol Struct Dynamics 39:1965–1974 Amadei A, Linssen ABM, Berendsen HJC (1993) Essential dynamics of proteins. Proteins 17:412–425 Valdés-Tresanco MS, Valdés-Tresanco ME, Valiente PA, Moreno E (2021) gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J Chem Theory Comput 17:6281–6291 Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717 Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem 58:4066–4072 Banerjee P, Eckert AO, Schrey AK, Preissner R (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46:W257–W263 Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO et al (2023) Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep 13:13398 Umar HI, Josiah SS, Saliu TP, Jimoh TO, Ajayi A, Danjuma JB (2021) In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. J Taibah Univ Med Sci 16:162–176 Mudi PK, Mahato RK, Verma H, Panda SJ, Purohit CS, Silakari O et al (2022) In silico anti-SARS-CoV-2 activities of five-membered heterocycle-substituted benzimidazoles. J Mol Struct 1261:132869 Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem 32:866–877 Huang Y, Rong C, Zhang R, Liu S (2017) Evaluating frontier orbital energy and HOMO/LUMO gap with descriptors from density functional reactivity theory. J Mol Model 23:3 Miar M, Shiroudi A, Pourshamsian K, Oliaey AR, Hatamjafari F (2021) Theoretical investigations on the HOMO–LUMO gap and global reactivity descriptor studies, natural bond orbital, and nucleus-independent chemical shifts analyses of 3-phenylbenzo[ d ]thiazole-2(3 H )-imine and its para -substituted derivatives: Solvent and substituent effects. J Chem Res 45:147–158 Chattaraj PK, Sarkar U, Roy DR (2006) Electrophilicity Index. Chem Rev 106:2065–2091 De Proft F, Geerlings P (2001) Conceptual and Computational DFT in the Study of Aromaticity. Chem Rev 101:1451–1464 Praveena R, Sadasivam K, Deepha V, Sivakumar R (2014) Antioxidant potential of orientin: A combined experimental and DFT approach. J Mol Struct 1061:114–123 Durrant JD, McCammon JA (2011) Molecular dynamics simulations and drug discovery. BMC Biol 9:71 Lee HS, Qi Y, Im W (2015) Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study. Sci Rep 5:8926 Faraj SE, González-Lebrero RM, Roman EA, Santos J (2016) Human Frataxin Folds Via an Intermediate State. Role of the C-Terminal Region. Sci Rep 6:20782 Ilyas U, Nazir B, Altaf R, Muhammad SA, Zafar H, Paiva-Santos AC et al (2022) Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives. Front Endocrinol 13:1022623 Sharma P, Joshi T, Joshi T, Chandra S, Tamta S (2021) Molecular dynamics simulation for screening phytochemicals as α-amylase inhibitors from medicinal plants. J Biomol Struct Dynamics 39:6524–6538 Chakravarty D, Guharoy M, Robert CH, Chakrabarti P, Janin J (2013) Reassessing buried surface areas in protein–protein complexes. Protein Sci 22:1453–1457 Chikalov I, Yao P, Moshkov M, Latombe J-C (2011) Learning probabilistic models of hydrogen bond stability from molecular dynamics simulation trajectories. BMC Bioinformatics 12:S34 Dutt M, Kumar A, Rout M, Dehury B, Martinez G, Ndishimye P et al (2023) Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA-dependent RNA polymerase using molecular modeling approach. J Cell Biochem 124:701–715 Maisuradze GG, Liwo A, Scheraga HA (2010) Relation between Free Energy Landscapes of Proteins and Dynamics. J Chem Theory Comput 6:583–595 Prada-Gracia D, Gómez-Gardeñes J, Echenique P, Falo F (2009) Exploring the Free Energy Landscape: From Dynamics to Networks and Back. Levitt M, editor. PLoS Comput Biol. ;5:e1000415 Baidya AT, Kumar A, Kumar R, Darreh-Shori T (2022) Allosteric Binding Sites of Aβ Peptides on the Acetylcholine Synthesizing Enzyme ChAT as Deduced by In Silico Molecular Modeling. IJMS 23:6073 UKumar S, Bithia R, TKumar D, Doss CGP, Zayed H (2022) Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach. J Biomol Struct Dynamics 40:1571–1585 Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449–461 Hefti FF (2008) Requirements for a lead compound to become a clinical candidate. BMC Neurosci 9:S7 Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214 Barrett JA, Yang W, Skolnik SM, Belliveau LM, Patros KM (2022) Discovery solubility measurement and assessment of small molecules with drug development in mind. Drug Discovery Today 27:1315–1325 Muehlbacher M, Spitzer GM, Liedl KR, Kornhuber J (2011) Qualitative prediction of blood–brain barrier permeability on a large and refined dataset. J Comput Aided Mol Des 25:1095–1106 Bibi Z (2008) Role of cytochrome P450 in drug interactions. Nutr Metab (Lond) 5:27 Xu C, Cheng F, Chen L, Du Z, Li W, Liu G et al (2012) In silico Prediction of Chemical Ames Mutagenicity. J Chem Inf Model 52:2840–2847 Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235–249 Doak BC, Over B, Giordanetto F, Kihlberg J (2014) Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chem Biol 21:1115–1142 Nakai M, Fukui Y, Asami S, Toyoda-Ono Y, Iwashita T, Shibata H et al (2005) Inhibitory Effects of Oolong Tea Polyphenols on Pancreatic Lipase in Vitro. J Agric Food Chem 53:4593–4598 Ivanov SA, Nomura K, Malfanov IL, Sklyar IV, Ptitsyn LR (2011) Isolation of a novel catechin from Bergenia rhizomes that has pronounced lipase-inhibiting and antioxidative properties. Fitoterapia 82:212–218 Additional Declarations The authors declare no competing interests. Supplementary Files LipaseSupplementary.docx Supporting Information Table S1: List of the selected metabolites. Table S2: Molecular docking results of the selected metabolites, Table S3: DFT results of (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3’-O-methyl gallate), Table S4: Drug-likeness of (-)-epicatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, (-)-Epicatechin-3-O-(3’-O-methyl gallate), and orlistat., Table S4: ADMET properties of selected metabolites, Table S5: ADMET properties of of (-)-epicatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, (-)-Epicatechin-3-O-(3'-O-methyl gallate), and orlistat, Table S6: Toxicity analysis of (-)-epicatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, (-)-Epicatechin-3-O-(3’-O-methyl gallate), and orlistat, Figure S1: Structure of selected metabolites. GA.png Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5360869","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":372197999,"identity":"3af9cae6-6fe5-4001-bdfb-3d17a2ae5548","order_by":0,"name":"Siddha Raj Upadhyaya","email":"","orcid":"https://orcid.org/0000-0003-1221-835X","institution":"Tribhuvan University","correspondingAuthor":false,"prefix":"","firstName":"Siddha","middleName":"Raj","lastName":"Upadhyaya","suffix":""},{"id":372198248,"identity":"c0f7cd98-d85d-4676-9a4a-3809d79891ef","order_by":1,"name":"Jyoti Bashyal","email":"","orcid":"https://orcid.org/0000-0001-6069-2975","institution":"Tribhuvan University","correspondingAuthor":false,"prefix":"","firstName":"Jyoti","middleName":"","lastName":"Bashyal","suffix":""},{"id":372198574,"identity":"c929ba44-73cb-4dee-a403-a67459f67ac8","order_by":2,"name":"Bimal Kumar Raut","email":"","orcid":"https://orcid.org/0000-0003-2064-6311","institution":"Tribhuvan University","correspondingAuthor":false,"prefix":"","firstName":"Bimal","middleName":"Kumar","lastName":"Raut","suffix":""},{"id":372198573,"identity":"11aa4681-0035-4586-a006-6887f9fc3f4e","order_by":3,"name":"Niranjan Parajuli","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0002-9233-6489","institution":"Tribhuvan University","correspondingAuthor":true,"prefix":"","firstName":"Niranjan","middleName":"","lastName":"Parajuli","suffix":""}],"badges":[],"createdAt":"2024-10-30 11:10:39","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-5360869/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5360869/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":67939606,"identity":"1b3c15aa-3e37-41ad-965a-27f2ee90b2b7","added_by":"auto","created_at":"2024-10-31 11:51:13","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":75991,"visible":true,"origin":"","legend":"\u003cp\u003eMolecular docking results (A) (-)-epigallocatechin-3-O-p-coumarate, (B) (+)-catechin-3-O-gallate, (C) (-)-epicatechin-3-O-(3'-O-methyl gallate)\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/de77263cee956924111f8279.png"},{"id":67940163,"identity":"21d337b0-bc86-4f70-8e7e-54cb948716c7","added_by":"auto","created_at":"2024-10-31 11:59:13","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":104499,"visible":true,"origin":"","legend":"\u003cp\u003eDFT result showing frontier orbitals and band gap of (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, (-)-epicatechin-3-O-(3'-O-methyl gallate), and orlistat (reference).\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/821d7a3051baf18660e40b53.png"},{"id":67940489,"identity":"2950dd45-7e8d-45d2-bf45-cb1eaa8a473e","added_by":"auto","created_at":"2024-10-31 12:07:13","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":120423,"visible":true,"origin":"","legend":"\u003cp\u003eRMSD plot of apo-protein along with screened ligand-protein complexes.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/50cb138f8ac69b491ef6b8e7.png"},{"id":67939610,"identity":"18a5d46b-3b8c-473b-a6c3-b94ae7e88833","added_by":"auto","created_at":"2024-10-31 11:51:13","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":81794,"visible":true,"origin":"","legend":"\u003cp\u003eRMSF plot of apo-protein along with selected metabolites-protein complexes.\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/7a7d1337e0c9f01ed9ff7a6c.png"},{"id":67939609,"identity":"986d2712-3ce0-4df7-bb41-3a21eaf7250d","added_by":"auto","created_at":"2024-10-31 11:51:13","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":106205,"visible":true,"origin":"","legend":"\u003cp\u003eRg plot of apo-protein and selected ligand-protein complexes.\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/81623b6e40958c46685ff0bd.png"},{"id":67939614,"identity":"52e51dc0-3452-4415-9e3b-575ead2ad61d","added_by":"auto","created_at":"2024-10-31 11:51:13","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":99186,"visible":true,"origin":"","legend":"\u003cp\u003eSASA plot of apo-protein and selected ligand-protein complexes.\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/b2e14ebfbd593c6f7f103b14.png"},{"id":67940490,"identity":"763604aa-5c85-4c73-a740-0d9bea106771","added_by":"auto","created_at":"2024-10-31 12:07:13","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":52494,"visible":true,"origin":"","legend":"\u003cp\u003eHydrogen bonding of selected compounds and orlistat with lipase within 100 ns simulation trajectory.\u003c/p\u003e","description":"","filename":"7.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/db334c00e078fb3fa83fa19c.png"},{"id":67940164,"identity":"938406e9-8455-4301-b7ef-a341a3bbe096","added_by":"auto","created_at":"2024-10-31 11:59:13","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":116111,"visible":true,"origin":"","legend":"\u003cp\u003eGibbs free energy landscape of (A): (+)-catechin-3-O-gallate complex, (B): (-)-epigallocatechin-3-O-p-coumarate complex, (C): (-)-epicatechin-3-O-(3’-O-methyl gallate) complex, (D): apo-protein, and (E): orlistat (reference) complex.\u003c/p\u003e","description":"","filename":"8.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/7c3fa38020e8395ebb88d882.png"},{"id":67940165,"identity":"0a7ee07b-703d-4aa5-8c89-467d3bcd5c49","added_by":"auto","created_at":"2024-10-31 11:59:13","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":206969,"visible":true,"origin":"","legend":"\u003cp\u003ePrincipal component analysis (PCA) of (A): (+)-catechin-3-O-gallate complex, (B): (-)-epigallocatechin-3-O-p-coumarate complex, (C): (-)-epicatechin-3-O-(3’-O-methyl gallate) complex, (D): apo-protein, and (E): orlistat (reference) complex.\u003c/p\u003e","description":"","filename":"9.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/f71dcd3906abf3742dd98d13.png"},{"id":67939617,"identity":"bba7144a-184f-49e5-9628-0075ba2aec57","added_by":"auto","created_at":"2024-10-31 11:51:13","extension":"png","order_by":10,"title":"Figure 10","display":"","copyAsset":false,"role":"figure","size":331548,"visible":true,"origin":"","legend":"\u003cp\u003eDynamic cross-correlation matrix of (A): (+)-catechin-3-O-gallate complex, (B): (-)-epigallocatechin-3-O-p-coumarate complex, (C): (-)-epicatechin-3-O-(3’-O-methyl gallate) complex, (D): apo-protein, and (E): orlistat (reference) complex.\u003c/p\u003e","description":"","filename":"10.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/70991da3fc87bfbe05f930cd.png"},{"id":67940565,"identity":"5bd78ca2-aec6-4711-95fd-170236554cfb","added_by":"auto","created_at":"2024-10-31 12:15:14","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2091764,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/bb901030-ca36-4403-8050-79bcf19df2ce.pdf"},{"id":67940168,"identity":"e75ab6ac-3fd3-4975-a4e2-af0b7763e50c","added_by":"auto","created_at":"2024-10-31 11:59:13","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":882956,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupporting Information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable S1\u003c/strong\u003e: List of the selected metabolites. \u003cstrong\u003eTable S2\u003c/strong\u003e: Molecular docking results of the selected metabolites, \u003cstrong\u003eTable S3\u003c/strong\u003e: \u0026nbsp;DFT results of (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3’-O-methyl gallate), \u003cstrong\u003eTable S4\u003c/strong\u003e: Drug-likeness of (-)-epicatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, (-)-Epicatechin-3-O-(3’-O-methyl gallate), and orlistat., \u003cstrong\u003eTable S4\u003c/strong\u003e: \u0026nbsp;ADMET properties of selected metabolites, \u003cstrong\u003eTable S5: \u003c/strong\u003eADMET properties of of (-)-epicatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, (-)-Epicatechin-3-O-(3\u0026amp;#39;-O-methyl gallate), and orlistat, \u003cstrong\u003eTable S6\u003c/strong\u003e: Toxicity analysis of (-)-epicatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, (-)-Epicatechin-3-O-(3’-O-methyl gallate), and orlistat, \u003cstrong\u003eFigure S1: \u003c/strong\u003eStructure of selected metabolites.\u003c/p\u003e","description":"","filename":"LipaseSupplementary.docx","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/1614d68d3a1e421954188822.docx"},{"id":67939611,"identity":"acb2cda1-64d9-4bb5-a88f-8901c2828b56","added_by":"auto","created_at":"2024-10-31 11:51:13","extension":"png","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":100063,"visible":true,"origin":"","legend":"","description":"","filename":"GA.png","url":"https://assets-eu.researchsquare.com/files/rs-5360869/v1/b249bdb848beee9a3fd37969.png"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003ePolyphenol Inhibition of Human Pancreatic Lipase: An In-Silico Study Towards Obesity Control\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eHuman pancreatic lipase (triacylglycerol acyl hydrolase EC3.1.1.3), secreted by the acinar cells of the pancreas, exhibits a strong preference for triacylglycerides and collaborates with bile salts in the gastrointestinal tract to hydrolyze them into fatty acids and glycerol [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. HPL is pivotal in regulating lipid metabolism by hydrolyzing 50\u0026ndash;70% of dietary fat [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] essential for lipid absorption. Inhibiting HPL effectively reduces triglyceride intake, offering a potential therapeutic strategy for obesity [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u0026mdash;a chronic medical condition characterized by excess adiposity, which affects approximately 650\u0026nbsp;million individuals globally. Lifestyle interventions, encompassing dietary adjustments, physical activity, and behavioral modifications, entail the primary approach to managing obesity [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Despite their implementation, these interventions typically yield an average weight loss of ~\u0026thinsp;10%. Maintaining this weight loss is challenging, with about 80% of the weight normally regained within five years [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Moreover, Obesity is linked with a spectrum of negative health consequences, encompassing metabolic disorders such as stroke, diabetes, atherosclerosis, cardiovascular diseases, hyperlipidemia, hypertension, chronic kidney disease, nonalcoholic fatty liver disease, and cancer alongside depression and osteoarthritis [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Its profound impact on health necessitates effective preventive and therapeutic interventions. Orlistat, the primary FDA-approved lipase inhibitor for managing obesity, functions by covalently binding to the active serine site of lipases, thereby inhibiting their ability to hydrolyze dietary fat. However, its use leads to gastrointestinal side effects and potential reductions in the absorption of fat-soluble vitamins [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Despite these drawbacks, it is chosen as a standard compound in obesity studies due to its unique mechanism and established efficacy, providing a reliable baseline for evaluating new treatments while ongoing research aims to develop alternatives that minimize side effects, improve patient adherence, and offer full health benefits.\u003c/p\u003e \u003cp\u003eHuman pancreatic lipase, located at10Q26 of the human chromosome [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e] is composed of 449 amino acids, with SER 152, HIS 263, and ASP 176 forming the conserved catalytic triad [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Its activity relies on the presence of colipase, and lipase inhibitors have shown efficacy in both preclinical and clinical obesity models [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Modulating the activity of human pancreatic lipase may offer new therapeutic approaches to inhibit fat absorption in the body, potentially aiding in treating obesity and associated metabolic disorders [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Natural products have high safety profiles, effectively inhibit pancreatic lipase, and have significant gastrointestinal exposure, making them advantageous in treating metabolic disorders associated with obesity( X.-D. Hou et al., 2022). Phytochemicals offer a promising alternative to current medication, addressing major issues related to gut microbiota and nutrient deficiencies, underscoring the necessity of managing side effects while targeting specific enzymes [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Key pharmacological actions that aid in obesity control include their effects on lipid metabolism and adipogenesis [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Polyphenols, in particular, demonstrate modest effects through multiple metabolic targets and pathways, such as suppression of food intake, inhibition of lipogenesis, enhancement of lipolysis, prevention of fatty acid oxidation, and inhibition of adipogenesis and apoptosis [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. The chemical structure, substitutions, and number of hydroxyl groups in polyphenols significantly affect their bioavailability and absorption. Consequently, these factors have a major influence on their biological activities, including their antioxidant characteristics, free radical scavenging, enhanced insulin sensitivity, reduced inflammation, and modulation of gut microbiota, providing synergistic benefits for obesity control [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eBreakthroughs in pharmaceutical sciences, like computer-aided screening (CAS), molecular docking, molecular dynamics (MD) simulations, and computer-aided drug design (CADD), are key to rapidly discovering potent drug compounds and refining methodologies in drug discovery and development [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. To explore potential new target sites, we developed a robust computational framework that encompasses docking, molecular mechanics using generalized Born and surface area solvation (MM/GBSA), molecular dynamics (MD) simulations, density functional theory (DFT), along with pharmacokinetic and toxicity assessments. This framework focuses on predicting the effectiveness of polyphenols as inhibitors of HPL. It emphasizes inhibitors that demonstrate strong binding affinities and maintain stable interaction poses with the catalytic sites. The analysis includes key stability indicators like root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), the radius of gyration (Rg), solvent-accessible surface area (SASA), and hydrogen bond interactions. These inhibitors are expected to bind efficiently to the target enzyme, exhibiting potent reactivity and kinetic stability, thereby effectively suppressing obesity.\u003c/p\u003e"},{"header":"2. Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Library of Compounds and Ligand Preparation\u003c/h2\u003e \u003cp\u003eA library of polyphenols, recognized for their reported in vitro antiobesity properties, was prepared to identify potential HPL inhibitors in context to their therapeutic purposes. The library of included metabolites in the library are presented in \u003cb\u003eTable S1\u003c/b\u003e and \u003cb\u003eFigure S1\u003c/b\u003e. The 3D conformer of each ligand sourced from the PubChem database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://pubchem.ncbi.nlm.nih.gov/\u003c/span\u003e\u003cspan address=\"https://pubchem.ncbi.nlm.nih.gov/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) was imported into the Flare workspace through their canonical SMILES. Utilizing a ligand prep module, each ligand was prepared by minimizing energy while maintaining a pH of 7.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Protein preparation and validation\u003c/h2\u003e \u003cp\u003eA lipase protein (PDB ID: 1LPB), with no mutation and 2.46 \u0026Aring; resolution, was retrieved from the protein data bank (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.rcsb.org/\u003c/span\u003e\u003cspan address=\"https://www.rcsb.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e and imported into the Flare workspace using the input protonation state. The protein prep module was then employed to prepare protein by; removing complexed ligands, capping residues, maintaining a pH of 7, allowing slight side chain movements, eliminating atoms from residues with incomplete backbones, discarding water molecules and unwanted chains, and filling gaps in residues.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Molecular Docking\u003c/h2\u003e \u003cp\u003eUtilizing Cresset Flare Flare Pro\u003csup\u003e+\u003c/sup\u003e software (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.cresset-group.com/flare/\u003c/span\u003e\u003cspan address=\"http://www.cresset-group.com/flare/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e], a molecular docking study of selected metabolites was performed. The grid size was created by enclosing the catalytic triad residues. The docking calculation was performed in normal mode, with the evaluation of the results based on their interaction and binding affinity. Lead Finder\u0026trade;, which features a specific algorithm and scoring functions for virtual screening, was applied in docking analysis. Validation of the procedure was achieved through redocking and superimposition, ensuring reliable and consistent outcomes [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4 MM/GBSA binding energy calculations\u003c/h2\u003e \u003cp\u003eThe MM/GBSA calculations were performed for the docked protein-ligand complex utilizing Cresset Flare Pro\u003csup\u003e+\u003c/sup\u003e software in normal mode with the default settings (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.cresset-group.com/flare\u003c/span\u003e\u003cspan address=\"https://www.cresset-group.com/flare\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.5 Electrostatic complementarity\u003c/h2\u003e \u003cp\u003eAn electrostatic complementarity analysis was carried out with the Flare Pro\u003csup\u003e+\u003c/sup\u003e module of Cresset software to assess the electrostatic compatibility between the selected ligands and the protein binding pocket [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Non-covalent interactions between small molecules and their receptors significantly impact the binding affinity of the protein-ligand complex. This evaluation provides details regarding the binding interactions of these ligands with the HPL targets.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.6 Density Functional Theory (DFT)\u003c/h2\u003e \u003cp\u003eDFT analysis utilizing GuassView 6 and Guassian 09 software ([\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e] with the Becke, 3-parameter, Lee-Yang-Parr (B3LYP) functional and the 6-31G (d,p) basis set was performed to assess the reactivity of listed phytochemicals and orlistat within the protein's catalytic domain [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. The band gap energy (ΔE) was calculated by computing the energies of the frontier molecular orbitals, specifically the highest occupied (E\u003csub\u003eHOMO\u003c/sub\u003e) and lowest unoccupied molecular orbital (E\u003csub\u003eLUMO\u003c/sub\u003e) [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. The formulae below were used to compute the ionization potential (I), electron affinity (A), chemical hardness (η), chemical softness (S), electronegativity (χ), electrophilicity index (⍵), and chemical potential (\u0026micro;) [\u003cspan additionalcitationids=\"CR30\" citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eEnergy difference of HOMO and LUMO (ΔE\u003csub\u003egap\u003c/sub\u003e )\u0026thinsp;=\u0026thinsp;E\u003csub\u003eLUMO\u003c/sub\u003e \u0026minus; E\u003csub\u003eHOMO\u003c/sub\u003e \u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;..(Eq.\u0026nbsp;1)\u003c/p\u003e \u003cp\u003eIonization potential (I)\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;E\u003csub\u003eHOMO\u003c/sub\u003e \u0026hellip;\u0026hellip;....................................................................(Eq.\u0026nbsp;2)\u003c/p\u003e \u003cp\u003eElectron affinity (A)\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;E\u003csub\u003eLUMO\u003c/sub\u003e \u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;(Eq.\u0026nbsp;3)\u003c/p\u003e \u003cp\u003eChemical (Global) hardness (η) = ΔE/2 \u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;.\u0026hellip;..(Eq.\u0026nbsp;4)\u003c/p\u003e \u003cp\u003eChemical softness (S)\u0026thinsp;=\u0026thinsp;1/η \u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;..(Eq.\u0026nbsp;5)\u003c/p\u003e \u003cp\u003eElectronegativity (χ) = (I\u0026thinsp;+\u0026thinsp;A) / 2 \u0026asymp; \u0026minus; \u0026micro; (chemical potential) \u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;..\u0026hellip;\u0026hellip;(Eq.\u0026nbsp;6)\u003c/p\u003e \u003cp\u003eElectrophilicity index (ω) = \u0026micro;\u003csup\u003e2\u003c/sup\u003e/2η \u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;\u0026hellip;...\u0026hellip;.(Eq.\u0026nbsp;7)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e2.7 Molecular Dynamics Simulation\u003c/h2\u003e \u003cp\u003eA 100 ns molecular dynamics (MD) simulation was performed using Gromacs software to evaluate the conformational dynamics and stability of the biomolecules [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. MD simulation focused on complexes with binding affinities\u0026thinsp;\u0026lt;\u0026thinsp;\u0026minus;\u0026thinsp;9.0 kcal/mol. The ligand topology file was initially developed using the Swissparam website [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e], while protein topology files were created using the CHARMM27 force field with a simple point charge (SPC) water model. Then the protein.gro and ligand.gro files were combined to create the complex.gro files. The complex was enclosed in a triclinic box under periodic boundary conditions and neutralized with Cl\u003csup\u003e\u0026minus;\u003c/sup\u003e or Na\u003csup\u003e+\u003c/sup\u003e ions. The steepest descent algorithm was employed to perform energy minimization for 5,000 steps. The system was then equilibrated under NVT conditions at 300 k temperature for 50,000 steps, followed by NTP conditions at 1 atm pressure for 50,000 steps (100 ps). The last step was to run a 100 ns MD simulation. The simulation results were analyzed using RMSD, RMSF, Rg, SASA, hydrogen bonding, and the free energy landscape (FEL) [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e2.8 Principal Component Analysis (PCA) and Dynamic Cross-Correlation Matrix (DCCM) Analysis\u003c/h2\u003e \u003cp\u003ePrincipal component analysis (PCA) was used using the Bio3d package in R Studio to evaluate the dynamic behavior and conformational space of biomolecules [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. The analysis involved evaluating the eigenvectors and eigenvalues, as well as their projections onto the initial three principal components [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. The variable dynamic behavior of complexes essential for biological activities was extracted through PCA [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. It was expected that stable protein-ligand complexes would exhibit reduced dynamic fluctuations due to the increased rigidity of the ligand-binding sites. Additionally, dynamic cross-correlation matrix (DCCM) analysis was conducted utilizing the Bio3D package [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e] to understand and compare the dynamic and conformational changes occurring in apo-protein and protein-ligand complexes.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e2.9 Molecular Mechanics Poisson-Boltzman Surface Area (MM/PBSA)\u003c/h2\u003e \u003cp\u003eProtein-ligand complex binding energies, which are necessary for MD simulations and thermodynamic assessments, were assessed using the gmx_MMPBSA module of the GROMACS software. The binding energy (ΔGbind) of protein and ligand complexes was determined using the well-known MM-PBSA technique in conjunction with MD simulations, as shown by the equation [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]:\u003c/p\u003e \u003cp\u003eΔG\u003csub\u003ebind\u003c/sub\u003e = G\u003csub\u003ecomplex\u003c/sub\u003e - (G\u003csub\u003ereceptor\u003c/sub\u003e + G\u003csub\u003eligand\u003c/sub\u003e)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e2.10 Pharmacokinetic Analysis\u003c/h2\u003e \u003cp\u003eThe physicochemical properties of the compounds were evaluated using the SwissADME drug-likeness online platform [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. Likewise, the ADMET and toxicity profile were accessed using pkCSM [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e] and ProTox-II web servers [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e], respectively.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. Results and Discussions","content":"\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Molecular Docking and MM/GBSA Calculation\u003c/h2\u003e \u003cp\u003eMolecular docking, a key approach in drug discovery, advances the prediction of enzyme inhibitors by offering a detailed insight into their interactions and effectiveness [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. Initially, the chosen polyphenols were evaluated through molecular docking, which involved analyzing binding scores and competitive interactions with catalytic residues to determine the most effective HPA inhibitor. To ensure the accuracy and reliability of the molecular docking process, redocking was performed, showing an RMSD value of under 2 \u0026Aring; for the ligand [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. After successful validation, the selected compound library was docked into the catalytic diad of HPL, and the results were analyzed regarding interaction with the active site, binding affinity, and MM/GBSA value. Docking results were expressed as LF (LigandFit) rank score, LF dG score, LF Vscore, and LF LE (LigandFit Ligand Efficiency) score. LF rank and dG here signify the exact ranking of each docked ligand pose by energy and the binding affinity, respectively, while VSscore and LE illustrate the correct ranking of compounds as active or inactive in virtual screening and the estimated efficiency of the ligand [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. These compounds showed LF Rank scores ranging from \u0026minus;\u0026thinsp;2.255 to -11.09, LF dG score from \u0026minus;\u0026thinsp;0.462 to -19.516, LF Vscore from \u0026minus;\u0026thinsp;4.377 to -12.689, LF LE score from \u0026minus;\u0026thinsp;0.015 to -0.61, and MM/GBSA from \u0026minus;\u0026thinsp;24.47 to -53.37 kcal/mol, compared to reference ligand orlistat, which exhibited an LF Rank score of 0.293, an LF dG of -8.343, an LF Vscore of -8.864, an LF LE of -0.238, and an MM/GBSA of -49.4 kcal/mol.\u003c/p\u003e \u003cp\u003eUsing MM/GBSA, which provides a prominent binding score [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e], three compounds\u0026mdash;(-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate)\u0026mdash;exhibited higher MM/GBSA of -53.29, -52.76, and \u0026minus;\u0026thinsp;53.37 kcal/mol, respectively, compared to orlistat (-49.4 kcal/mol). Their interactions with catalytic residues, as detailed in \u003cb\u003eTable S2\u003c/b\u003e, underscore their significance in inhibiting HPL. (-)-epigallocatechin-3-O-p-coumarate showed hydrogen bonds interaction with SER 152 (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA and Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e), a catalytic residue accountable for the hydrolysis of triglycerides into smaller absorbable forms, thereby managing obesity. The active site residues SER 152 and HIS 263 formed strong hydrogen bonds with (+)-catechin-3-O-gallate (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). Similarly, (-)-epicatchein-3-O-(3'-O-methyl gallate) exhibited catalytic inhibition via hydrogen bonds with SER 152 (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC). These compounds demonstrated potency for competitive inhibition through interactions with catalytic site residues and higher MM/GBSA values (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e), indicating a need for further investigation with additional \u003cem\u003ein-silico\u003c/em\u003e analyses.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMolecular docking and MM/GBSA results\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCompound\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLF Rank score\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eLF dG\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eLF Vscore\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLF LE\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eInteractions\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eMM/GBSA\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epigallocatechin-3-O-p-coumarate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-5.601\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-8.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-9.928\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e-0.246\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eH-bond: GLY76, ASP79, TYR114, HIS151, SER152\u003c/p\u003e \u003cp\u003eAromatic-Aromatic: TYR114\u003c/p\u003e \u003cp\u003eCation-pi: HIS263\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e-53.29\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(+)-catechin-3-O-gallate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-10.381\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-10.166\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-10.821\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e-0.318\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eH-bond: GLY76, PHE77, ASP79, TYR114, SER152, PHE215, HIS263\u003c/p\u003e \u003cp\u003eAromatic-Aromatic: PHE77, HIS151, PHE215, HIS263\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e-52.76\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epicatechin-3-O-(3'-O-methyl gallate)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-10.377\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-10.751\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-11.617\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e-0.326\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eH-bond: GLY76, ASP79, HIS151, SER152, PHE215, ARG256, HIS263\u003c/p\u003e \u003cp\u003eAromatic-Aromatic: PHE215, and HIS263\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e-53.37\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOrlistat\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.293\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-8.343\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-8.864\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e-0.238\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eH-bond: PHE77, SER152, HIS263\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e-49.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003e3.2 Electrostatic complementarity\u003c/h2\u003e \u003cp\u003eThe three screened ligands\u0026mdash;(-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) were subjected for electrostatic complementarity analysis in context to EC, EC r and EC rho. EC is a normalized complementarity score surface integral that effectively provides the average score throughout the surface of the ligand, while EC r and EC rho represent the Spearman rank correlation coefficient and Pearson's correlation coefficient, respectively. The electrostatic potential of proteins and ligands sampled on the surface vertices is often computed using these scores [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. These scores' metrics vary, but they often fall between 1 (perfect complementarity) and \u0026minus;\u0026thinsp;1 (complete clash). As shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e, all three ligands were found to manifest better electrostatic complementarity scores with no indication of steric clashes, thereby indicating their potential for HPL inhibition.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eElectrostatic complementarity results of (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCompounds\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eEC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eEC r\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEC rho\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epigallocatechin-3-O-p-coumarate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.198\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.118\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.128\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(+)-catechin-3-O-gallate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.192\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.097\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.057\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epicatechin-3-O-(3'-O-methyl gallate)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.081\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003e3.3 DFT\u003c/h2\u003e \u003cp\u003eThe reactivity of ligands in catalytic site of HPL was evaluated using a DFT study. The band-gap energy, which is the difference between the LUMO and HOMO energies (E\u003csub\u003eLUMO\u003c/sub\u003e \u0026minus; E\u003csub\u003eHOMO\u003c/sub\u003e), serves as an indicator of molecular reactivity. Ligands with a smaller band-gap energy are more polarizable and exhibit higher chemical reactivity [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. As displayed in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e, the hit compounds showed higher reactivity with lower band gap energy compared to the reference compound orlistat. Furthermore, their ionization energy and electron affinity indicate greater reactivity, indicating their capabilities to donate and attract electrons [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTo better comprehend the protein-ligand interaction and the effectiveness of the drug, quantum mechanical parameters of chemical hardness (η), softness (S), electronegativity (χ), electrophilic index (ω), and chemical potential (\u0026micro;) play crucial roles. These parameters characterize the ligand's reactivity and chemical stability. The χ indicates a molecule's ability to attract electrons, η, and S denotes the presence of barriers to electron flow, ω represents the energy lost as a result of the electrons flowing between them, and \u0026micro; marks the electron transfer path [\u003cspan additionalcitationids=\"CR50\" citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. When compared to the orlistat, all of the previously described metrics, as displayed in \u003cb\u003eTable S3\u003c/b\u003e, the hit compounds showed excellent efficacy of reactivity in the binding pocket of HPL.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003e3.4 Molecular Dynamic Simulation\u003c/h2\u003e \u003cp\u003eIn computational-aided drug design (CADD), MD simulations are pivotal by revealing complex molecular behaviors at atomic and molecular levels. They also contribute to a deeper understanding of protein or enzyme interactions with drug targets, thereby facilitating the optimization of drug candidates [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e].\u003c/p\u003e \u003cdiv id=\"Sec18\" class=\"Section3\"\u003e \u003ch2\u003e3.4.1 Root mean square deviation (RMSD)\u003c/h2\u003e \u003cp\u003eThrough RMSD analysis, dynamic behaviors were explored, uncovering shifts in conformation and structural modifications in the backbone of both apoprotein and protein-ligand complexes [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e]. Additionally, it facilitates the comparison of the native folded protein structure with its partly or completely unfolded counterparts, serving as a valuable reaction coordinate in protein folding studies [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. The RMSD plot of all complexes is displayed in Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e. The RMSD graph revealed that all selected complexes along with apo-proprotein gain remarkable stability within a 20 ns simulation trajectory. Although the RMSD value of the orlistat complex is lower than that of the selected candidates, it achieves stability only after 60 ns of simulation trajectory. The apo-protein has the lowest RMSD value with an average of 0.18 nm, followed by the orlistat-protein complex with an average of 0.24 nm. The (-)-epigallocatechin-3-O-p-coumarate complex has an average RMSD value of 0.33 nm, (+)-catechin-3-O-gallate has 0.36 nm, and (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) complex has 0.41 nm. The average RMSD values for each complex, including the apo-protein, are presented in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMD simulation results spanning 100 ns for (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate)\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplex\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAverage RMSD (nm)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAverage RMSF (nm)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAverage Rg (nm)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAverage SASA (nm\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(+)-Catechin-3-O-gallate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e238.99\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epigallocatechin-3-O-p-coumarate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e237.49\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e236.50\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eApo-protein\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e234.54\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOrlistat (reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e237.09\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section3\"\u003e \u003ch2\u003e3.4.2 Root mean square fluctuations (RMSF)\u003c/h2\u003e \u003cp\u003eRMSF assesses the displacement of particular atoms or groups of atoms from the reference structure, averaged across all atoms. It is employed to investigate the dynamic behavior of specific amino acids within the protein-ligand complexes' backbone. Higher RMSF values suggest increased flexibility and mobility in specific protein regions, providing insights into the characteristics of protein loops and protease-labile segments [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. Likewise, secondary protein structures like helices and sheets are stable when their RMSF value is lower. All complexes along with the apo-protein exhibited fluctuations in similar regions. The current study revealed orlistat complex showed the lowest fluctuations with an average fluctuation of 0.09 nm, followed by apo-protein with an average RMSF of 0.11 nm, (+)-catechin-3-O-gallate complex and (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) complex have an average RMSF of 0.13 nm (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). In addition, (-)-epigallocatechin-3-O-p-coumarate complex exhibited the highest RMSF with an average of 0.14 nm. Figure\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e shows that high levels of fluctuation were observed in VAL210, PRO211, ASN240 to THR255, GLN233, GLY348 to HIS354, LYS 363, THR375 to ASP379, and TYR403 to ARG414 amino acid residues, none of which are part of the catalytic site.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section3\"\u003e \u003ch2\u003e3.4.3 Radius of gyration (Rg)\u003c/h2\u003e \u003cp\u003eThe stability of the selected complexes and apo-protein was evaluated using the radius of gyration (Rg). This measure was analyzed over a 100 ns simulation trajectory to assess the structural compactness, stability, and conformational states of the complexes and the apo-protein [\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. The MD simulation results showed that all protein-ligand complexes exhibited Rg values nearly comparable to those of the apo-protein, indicating all ligands bind effectively in the binding pocket of the protein. (+)-catechin-3-O-gallate-protein and (-)-epicatechin-3-O-p-coumarate-protein complexes exhibited equal Rg value of 2.63 nm, suggesting both complexes have comparable stability. The (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate)-protein complex displayed the highest average Rg value of 2.65 nm, while the orlistat (reference)-protein complex exhibited a slightly lower average Rg value of 2.61 nm (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). The Rg values obtained during the 100 ns simulation trajectory indicate that all the protein-ligand complexes achieved a relatively stable folded conformation. In summary, the Rg graph (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e) demonstrated that all the selected compounds, along with the reference, bind effectively with the protein and form more compact structures.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section3\"\u003e \u003ch2\u003e3.4.4 Solvent accessible surface area (SASA)\u003c/h2\u003e \u003cp\u003eThe solvent-accessible surface area (SASA) parameter quantifies the area of the protein and protein-ligand complex that is exposed to organic solvents and water. SASA is crucial for assessing the extent of conformational changes during interactions. Typically, the bound conformation of biomolecules exhibits a higher SASA value in comparison to their unbound state [\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e]. A lower SASA value suggests a more compact structure with less surface area available for solvent interactions. The apo-protein, in its unbound conformation, has the lowest SASA value, averaging 234.54 nm\u0026sup2;, while the protein-ligand complexes have slightly higher SASA values. The (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) complex has the lowest average SASA value compared to the other protein-ligand complex (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e), suggesting (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) bind strongly in the binding pocket of the protein, making the complex more compact. Similarly, orlistat complex has an average SASA value of 237.09 nm\u003csup\u003e2\u003c/sup\u003e, (+)-catechin-3-O-gallate complex has an average of 238.99 nm\u003csup\u003e2\u003c/sup\u003e, and (-)-epicatechin-3-O-p-coumarate complex has 237.49 nm\u003csup\u003e2\u003c/sup\u003e (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e. Overall, all the protein-ligand complexes have lower SASA values, which suggests all the ligands bind effectively in the binding site of the protein and make the complex more compact.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section3\"\u003e \u003ch2\u003e3.4.5 Hydrogen bonding\u003c/h2\u003e \u003cp\u003eGiven the importance of hydrogen bonds in ligand binding and their influence on biological functions like as metabolism, adsorption, drug affinity, and specificity, analyzing hydrogen-bonding patterns during the MD simulation is crucial. Assessing hydrogen bond interactions is a key step in elucidating and characterizing the molecular interaction patterns of protein-ligand complexes through molecular dynamics simulations [\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e, \u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e]. In the current investigation, we analyzed hydrogen bonds from MD trajectory to assess the stability between lipase and the potent ligands. It was observed that all the complexes constantly retained hydrogen bonds across the 100 ns simulation trajectory, as shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003e. (-)-epigallocatechin-3-O-p-coumarate and (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) complex exhibited the highest of five hydrogen bonds during 100 ns simulation trajectory. The Orlistat complex was found to have up to four hydrogen bonds and the (+)-catechin-3-O-gallate complex exhibited a maximum of two hydrogen bonds. These hydrogen-bond observations revealed that all ligands were effectively and securely bound to the enzymes through hydrogen bonding.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003e3.5 Free energy landscape\u003c/h2\u003e \u003cp\u003eProper folding and confirmation are crucial for biomolecules to function correctly. FEL aids in evaluating the conformational variability and free energy of protein structures. Conformational diversity assesses how diverse the sampled conformations are, while the free energy parameter provides insight into their relative stability and accessibility [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e]. These insights into conformational dynamics provide valuable perspectives for understanding protein biological functions and guiding the development of inhibitors or drugs [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e]. The Gibbs free energy landscape was determined utilizing \u003cem\u003egmx_covar\u003c/em\u003e, \u003cem\u003egmx_anaeig\u003c/em\u003e, and \u003cem\u003egmx_sham\u003c/em\u003e, based on the projections of their first (PC1) and second (PC2) eigenvectors, respectively. In the FEL plot, a red spot indicates a folded macromolecular structure with low Gibbs free energy, whereas a blue spot signifies an unfolded structure with high Gibbs free energy [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e]. A yellow spot denotes intermediate energy, while green represents the metastable frame duration of biomolecules. The figure of Gibbs free energy is displayed in Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003e. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003e (B), lipase gained a more folded structure after forming a complex with (-)-epigallocatechin-3-O-p-coumarate, while orlistat-lipase resulted in an unfolded structure. Overall, all three selected ligands gained folded structure after binding with protein. In conclusion, the free energy landscape plot, which reflects conformational changes, demonstrated the overall stability of biomolecules when complexed with (+)-catechin-3-O-gallate, (-)-epigallocatechin-3-O-p-coumarate, (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate), and orlistat.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003e3.6 Principal component analysis (PCA) and dynamic cross-correlation matrix (DCCM) analysis\u003c/h2\u003e \u003cp\u003ePrincipal component analysis (PCA) was conducted on the Cα atoms for both the apo-protein and the protein-ligand complex trajectories. PCA revealed the initial seven eigenvectors of apo-protein as well as (+)-catechin-3-O-gallate and (-)-epigallocatechin-3-O-p-coumarate complexes accounted more than 90% of movement, whereas, (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) complex account around 50% of movement and orlistat (reference) complex accounted only around 38% of movement. (+)-catechin-3-O-gallate and (-)-epigallocatechin-3-O-p-coumarate explored significantly larger conformational space (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003e). PCA assessment of the root mean square fluctuation (RMSF) showed heightened fluctuations in the loop region of the apo-protein after ligand binding. This is because loops typically have more fluctuations compared to helices. Such increased fluctuations are indicative of conformational changes in the apo-protein. Comparable flexibility in PC1 and PC2 was observed for (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) when compared to the apo-protein. Whereas, (+)-catechin-3-O-gallate and (-)-epigallocatechin-3-O-p-coumarate exhibited increased flexibility in the binding site of apo-protein, on the other hand, orlistat showed reduced flexibility.\u003c/p\u003e \u003cp\u003eAdditionally, the evaluation of the dynamic cross-correlation matrix was evaluated using the Cα atom coordinates from the 100 ns molecular dynamics trajectories. The result of the DCCM analysis is displayed in Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003e. The DCCM plot of (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate)-complex indicates a slight overall increase in negatively correlated motion upon ligand binding, whereas (+)-catechin-3-O-gallate showed a much greater increase in anti-correlated motion. In contrast, (-)-epigallocatechin-3-O-p-coumarate exhibited overall positively correlated motions. The highest negatively correlated motion was observed for (+)-catechin-3-O-gallate complex. Orlistat (reference) complex showed reduced correlation in motion. In brief, compared to the apo-protein, negatively correlated motions in the binding pocket of protein increase upon the binding of potent ligands. Therefore, it is likely to be concluded that the binding of selected phytochemicals creates a more stable environment compared to the orlistat.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec25\" class=\"Section2\"\u003e \u003ch2\u003e3.7 Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA)\u003c/h2\u003e \u003cp\u003eThe MM/PBSA approach, which combines molecular mechanics with Poisson-Boltzmann surface area continuum solvation, is a utilized method technique for calculating the binding free energy of protein-ligand complexes [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e]. Thus, the MMPBSA analysis combined with MD simulations demonstrated significant differences in the free-binding energies of the studied compounds, as illustrated in Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e. Particularly, (+)-catechin-3-O-gallate complex exhibited significant binding energy of -59.46 kcal/mol, (-)-epigallocatechin-3-O-p-coumarate complex unveiled a binding affinity of -56.54 kcal/mol, and the (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) complex demonstrated the binding energy of -48.48 kcal/mol. In contrast, the orlistat complex displayed a comparatively low binding energy of 40.26 kcal/mol. These results highlight the strong binding properties of (+)-catechin-3-O-gallate, (-)-epigallocatechin-3-O-p-coumarate complex, and (-)-epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate compared to the reference ligand orlistat.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eFree binding energy of protein-ligand complex through MMPBSA\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplex\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eΔG\u003csub\u003ecomplex\u003c/sub\u003e (kcal mol\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eΔG\u003csub\u003eprotein\u003c/sub\u003e (kcal mol\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eΔG\u003csub\u003eligand\u003c/sub\u003e (kcal mol\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eΔG\u003csub\u003ebind\u003c/sub\u003e (MM/PBSA) (kcal mol\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(+)-Catechin-3-O-gallate complex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1604.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1639.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e24.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e-59.46\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epigallocatechin-3-O-p-coumarate complex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1612.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1646.54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e22.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e-56.54\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(-)-Epicatechin-3-O-(3\u0026rsquo;-O-methyl gallate) complex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1607.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1629.64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e26.12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e-48.48\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOrlistat complex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1608.89\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1642.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e6.70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e40.26\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section2\"\u003e \u003ch2\u003e3.8 \u003cem\u003eIn Silico\u003c/em\u003e pharmacokinetic study\u003c/h2\u003e \u003cp\u003eA compound must exhibit high selectivity and minimal adverse effects to be considered a potential drug candidate [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e]. The effectiveness and eventual appearance of side effects attributed mostly to the compound's ADMET properties lead to a high attrition rate in the final phase of drug development [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e]. However, the likelihood of failure for a promising candidate can be reduced by using in-silico techniques. Hence, the drug-likeness and ADMET parameters of the potent candidates, (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate), were thoroughly evaluated and displayed in \u003cb\u003eTable S4\u003c/b\u003e and \u003cb\u003eTable S5\u003c/b\u003e respectively.\u003c/p\u003e \u003cp\u003eFor a successful drug candidate, solubility is a crucial physicochemical property[\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e]. SwissADME\u0026rsquo;s ESOL, Ali, and SILICOS-IT models, a solubility parameter[\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e], predicted (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) as soluble and (-)-epigallocatechin-3-O-p-coumarate as moderate soluble (\u003cb\u003eTable S4\u003c/b\u003e). All these three hit compounds surpass the minimal intestinal absorption criteria of 30%. Similarly, these compounds were found to be safer based on blood-brain barrier (BBB) permeability and log VDss, which indicate absorption into the brain that results in neurotoxicity and distribution in the tissues, respectively [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e]. Drug metabolism and the detoxification of foreign substances are greatly aided by cytochrome P450 enzymes, particularly CYP3A4 [\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e], the hit compounds don't inhibit CYP3A4, and therefore possess no negative effects and are readily metabolized in the liver. AMES toxicity and hepatotoxicity are crucial factors in assessing drug-induced liver injury and mutagenicity [\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e]. The hit compounds showed no AMES toxicity and hepatotoxicity, thereby indicating non\u0026ndash;mutagenicity and non-drug-induced liver injury (\u003cb\u003eTable S5\u003c/b\u003e). Moreover, the hit compounds were further subjected to drug-likeness Lipinski\u0026rsquo;s rule and Veber's rule to assess whether the hit compounds have drug-like properties or not. As per the Lipinski's rule of five criteria [\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e]\u0026mdash;molecular weight\u0026thinsp;\u0026le;\u0026thinsp;500 Da, log P\u0026thinsp;\u0026le;\u0026thinsp;5, hydrogen bond donors\u0026thinsp;\u0026le;\u0026thinsp;5, and hydrogen bond acceptors\u0026thinsp;\u0026le;\u0026thinsp;10\u0026mdash;and Veber's rule [\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e]\u0026mdash;TPSA\u0026thinsp;\u0026gt;\u0026thinsp;140 \u0026Aring;\u0026sup2; and rotatable bonds\u0026thinsp;\u0026le;\u0026thinsp;10\u0026mdash;the hit compounds exhibited better drug-like properties compared to the reference compound, orlistat.\u003c/p\u003e \u003cp\u003eThe hit compounds\u0026mdash;(-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate), therefore, demonstrated favorable pharmacokinetic properties, including significant intestinal absorption, acceptable drug-like behavior, good bioavailability, non-inhibition of cytochrome P450, and minimal toxicity (\u003cb\u003eTable S6\u003c/b\u003e).\u003c/p\u003e \u003cp\u003eTea polyphenols have been effective in controlling obesity by inhibiting human pancreatic lipase, thereby reducing fat absorption [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e]. Our potent compounds through \u003cem\u003ein silico\u003c/em\u003e analysis\u0026mdash;(+)-catechin-3-O-gallate, (-)-epigallocatechin-3-O-p-coumarate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) found to demonstrate significant \u003cem\u003ein vitro\u003c/em\u003e inhibition assay with IC\u003csub\u003e50\u003c/sub\u003e value of 4.57 [\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e], 0.835, and 0.68 \u0026micro;M [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e], respectively. These results indicate their potential effectiveness in controlling obesity.\u003c/p\u003e \u003c/div\u003e"},{"header":"4. Conclusion","content":"\u003cp\u003eEncompassing a diverse range of plant species and dietary sources, polyphenols are a heterogeneous group of secondary metabolites that have gained remarkable concentration in the present days for their potential health benefits, especially the ability to control obesity. Our extensive in-silico study on a library of polyphenols has identified (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) as potent inhibitors of HPL. These polyphenols demonstrated significant binding affinity and interactions with the catalytic residues of HPL, supported by high MM/GBSA values. Further validation through DFT studies and MDs simulations in regards to RMSD, RsMSF, Rg, SASA, and H-bonding confirmed the strong reactivity and stability of these compounds in the catalytic region of HPL. Similarly, the FEL plot revealed all selected protein-ligand complexes gained folded conformation, and the PCA and DCCM plots showed stable dynamic behavior of complexes after 100 ns simulation trajectory. Additionally, post-simulation MM/PBSA analysis indicated favorable binding free energy and ADMET and drug-likeness assessments affirmed their potential as effective and safe therapeutic agents for obesity management. These findings indicate that the identified polyphenols could be promising candidates for the development of anti-obesity therapeutics. However, future research should be carried out to experimentally validate these findings through pharmacokinetics studies.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe would like to acknowledge Cresset-group for providing the license of Flare and Spark software.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere was no funding for this research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of Interest Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors report there are no competing interests to declare.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eS.R.U. performed computational work, analyzed data, and wrote the manuscript; J.B. did a literature review, analyzed data, and drafted the manuscript; B.K.R. performed \u003cem\u003ein silico\u003c/em\u003e and drafted the manuscript and N.P. supervised the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical Approval\u003c/strong\u003e: Ethical approval was not necessary for this computational study since it did not involve animals, human participants, or identifiable data.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eKumar A, Chauhan S (2021) Pancreatic lipase inhibitors: The road voyaged and successes. Life Sci 271:119115\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMukherjee M (2003) Human digestive and metabolic lipases\u0026mdash;a brief review. J Mol Catal B: Enzymatic 22:369\u0026ndash;376\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWhitcomb DC, Lowe ME (2007) Human Pancreatic Digestive Enzymes. Dig Dis Sci 52:1\u0026ndash;17\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLowe ME (1994) Pancreatic triglyceride lipase and colipase: Insights into dietary fat digestion. Gastroenterology 107:1524\u0026ndash;1536\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMelson E, Ashraf U, Papamargaritis D, Davies MJ (2024) What is the pipeline for future medications for obesity? Int J Obes [Internet]. [cited 2024 Aug 6]; \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.nature.com/articles/s41366-024-01473-y\u003c/span\u003e\u003cspan address=\"https://www.nature.com/articles/s41366-024-01473-y\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHall KD, Kahan S (2018) Maintenance of Lost Weight and Long-Term Management of Obesity. Med Clin North Am 102:183\u0026ndash;197\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLin X, Li H, Obesity (2021) Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol 12:706978\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSwinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML et al (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:804\u0026ndash;814\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcClendon KS, Riche DM, Uwaifo GI (2009) Orlistat: current status in clinical therapeutics. Exp Opin Drug Saf 8:727\u0026ndash;744\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDavis RC, Diep A, Hunziker W, Klisak I, Mohandas T, Schotz MC et al (1991) Assignment of human pancreatic lipase gene (PNLIP) to chromosome 10q24\u0026ndash;q26. Genomics 11:1164\u0026ndash;1166\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEgloff M-P, Marguet F, Buono G, Verger R, Cambillau C, Van Tilbeurgh H (1995) The 2.46.ANG. Resolution Structure of the Pancreatic Lipase-Colipase Complex Inhibited by a C11 Alkyl Phosphonate. Biochemistry 34:2751\u0026ndash;2762\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu T-T, Liu X-T, Chen Q-X, Shi Y (2020) Lipase Inhibitors for Obesity: A Review. Biomed Pharmacother 128:110314\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eD\u0026rsquo;Agostino D, Lowe ME (2004) Pancreatic Lipase-related Protein 2 Is the Major Colipase-Dependent Pancreatic Lipase in Suckling Mice. J Nutr 134:132\u0026ndash;134\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHou X-D, Qin X-Y, Hou J, Tang H, Ge G-B (2022) The potential of natural sources for pancreatic lipase inhibitors: a solution of the obesity crisis? Expert Opin Drug Discov 17:1295\u0026ndash;1298\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHossen I, Hua W, Ting L, Mehmood A, Jingyi S, Duoxia X et al (2020) Phytochemicals and inflammatory bowel disease: a review. Crit Rev Food Sci Nutr 60:1321\u0026ndash;1345\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSudheer S, Gangwar P, Usmani Z, Sharma M, Sharma VK, Sana SS et al (2022) Shaping the gut microbiota by bioactive phytochemicals: An emerging approach for the prevention and treatment of human diseases. Biochimie 193:38\u0026ndash;63\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R et al (2014) Novel insights of dietary polyphenols and obesity. J Nutr Biochem 25:1\u0026ndash;18\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHe Q, Lv Y, Yao K (2007) Effects of tea polyphenols on the activities of α-amylase, pepsin, trypsin and lipase. Food Chem 101:1178\u0026ndash;1182\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSingh M, Thrimawithana T, Shukla R, Adhikari B (2020) Managing obesity through natural polyphenols: A review. Future Foods 1\u0026ndash;2:100002\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGasmi A, Mujawdiya PK, Noor S, Lysiuk R, Darmohray R, Piscopo S et al (2022) Polyphenols Metabolic Dis Molecules 27:6280\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAzad I, Khan T, Ahmad N, Khan AR, Akhter Y (2023) Updates on Drug Designing Approach Through Computational Strategies: a Review. Future Sci OA 9:FSO862\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoda S, Fernandez-Lopez L, Ca\u0026ntilde;adas R, Santiago G, Ferrer M, Guallar V (2021) Computationally Driven Rational Design of Substrate Promiscuity on Serine Ester Hydrolases. ACS Catal 11:3590\u0026ndash;3601\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheeseright T, Mackey M, Rose S, Vinter A (2006) Molecular Field Extrema as Descriptors of Biological Activity: Definition and Validation. J Chem Inf Model 46:665\u0026ndash;676\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eElekofehinti OO, Ejelonu OC, Kamdem JP, Akinlosotu OB, Famuti A, Adebowale DD et al (2018) Discovery of potential visfatin activators using in silico docking and ADME predictions as therapy for type 2 diabetes. Beni-Suef Univ J Basic Appl Sci 7:241\u0026ndash;249\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuhn M, Firth-Clark S, Tosco P, Mey ASJS, Mackey M, Michel J (2020) Assessment of Binding Affinity via Alchemical Free-Energy Calculations. J Chem Inf Model 60:3120\u0026ndash;3130\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBauer MR, Mackey MD (2019) Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein\u0026ndash;Ligand Complexes. J Med Chem 62:3036\u0026ndash;3050\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGaussian 09 Citation | Gaussian.com [Internet]. [cited 2024 Aug 16]. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://gaussian.com/g09citation/\u003c/span\u003e\u003cspan address=\"https://gaussian.com/g09citation/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGill PMW, Johnson BG, Pople JA, Frisch MJ (1992) The performance of the Becke\u0026mdash;Lee\u0026mdash;Yang\u0026mdash;Parr (B\u0026mdash;LYP) density functional theory with various basis sets. Chem Phys Lett 197:499\u0026ndash;505\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAL-Ishaq (2019) Abotaleb, Kubatka, Kajo, B\u0026uuml;sselberg. Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels. Biomolecules 9:430\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKumar CBP, Raghu MS, Prasad KNN, Chandrasekhar S, Jayanna BK, Alharthi FA et al (2021) Investigation of biological activity of 2,3-disubstituted quinazolin-4(1 \u003cem\u003eH\u003c/em\u003e)-ones against \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e and DNA \u003cem\u003evia\u003c/em\u003e docking, spectroscopy and DFT studies. New J Chem 45:403\u0026ndash;414\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOyewole RO, Oyebamiji AK, Semire B (2020) Theoretical calculations of molecular descriptors for anticancer activities of 1, 2, 3-triazole-pyrimidine derivatives against gastric cancer cell line (MGC-803): DFT, QSAR and docking approaches. Heliyon 6:e03926\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbraham MJ, Murtola T, Schulz R, P\u0026aacute;ll S, Smith JC, Hess B et al (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u0026ndash;2:19\u0026ndash;25\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePronk S, P\u0026aacute;ll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R et al (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29:845\u0026ndash;854\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: A fast force field generation tool for small organic molecules. J Comput Chem 32:2359\u0026ndash;2368\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbraham M, Alekseenko A, Bergh C, Blau C, Briand E, Doijade M et al (2023) GROMACS 2023 Manual. [cited 2024 Aug 6]; \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://zenodo.org/record/7588711\u003c/span\u003e\u003cspan address=\"https://zenodo.org/record/7588711\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGrant BJ, Rodrigues APC, ElSawy KM, McCammon JA, Caves LSD (2006) Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22:2695\u0026ndash;2696\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAl-Khafaji K, Taskin Tok T (2021) Amygdalin as multi-target anticancer drug against targets of cell division cycle: double docking and molecular dynamics simulation. J Biomol Struct Dynamics 39:1965\u0026ndash;1974\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmadei A, Linssen ABM, Berendsen HJC (1993) Essential dynamics of proteins. Proteins 17:412\u0026ndash;425\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVald\u0026eacute;s-Tresanco MS, Vald\u0026eacute;s-Tresanco ME, Valiente PA, Moreno E (2021) gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J Chem Theory Comput 17:6281\u0026ndash;6291\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDaina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePires DEV, Blundell TL, Ascher DB (2015) pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem 58:4066\u0026ndash;4072\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBanerjee P, Eckert AO, Schrey AK, Preissner R (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46:W257\u0026ndash;W263\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAgu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO et al (2023) Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep 13:13398\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUmar HI, Josiah SS, Saliu TP, Jimoh TO, Ajayi A, Danjuma JB (2021) In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. J Taibah Univ Med Sci 16:162\u0026ndash;176\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMudi PK, Mahato RK, Verma H, Panda SJ, Purohit CS, Silakari O et al (2022) In silico anti-SARS-CoV-2 activities of five-membered heterocycle-substituted benzimidazoles. J Mol Struct 1261:132869\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem 32:866\u0026ndash;877\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang Y, Rong C, Zhang R, Liu S (2017) Evaluating frontier orbital energy and HOMO/LUMO gap with descriptors from density functional reactivity theory. J Mol Model 23:3\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMiar M, Shiroudi A, Pourshamsian K, Oliaey AR, Hatamjafari F (2021) Theoretical investigations on the HOMO\u0026ndash;LUMO gap and global reactivity descriptor studies, natural bond orbital, and nucleus-independent chemical shifts analyses of 3-phenylbenzo[ \u003cem\u003ed\u003c/em\u003e ]thiazole-2(3 \u003cem\u003eH\u003c/em\u003e)-imine and its \u003cem\u003epara\u003c/em\u003e -substituted derivatives: Solvent and substituent effects. J Chem Res 45:147\u0026ndash;158\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChattaraj PK, Sarkar U, Roy DR (2006) Electrophilicity Index. Chem Rev 106:2065\u0026ndash;2091\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDe Proft F, Geerlings P (2001) Conceptual and Computational DFT in the Study of Aromaticity. Chem Rev 101:1451\u0026ndash;1464\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePraveena R, Sadasivam K, Deepha V, Sivakumar R (2014) Antioxidant potential of orientin: A combined experimental and DFT approach. J Mol Struct 1061:114\u0026ndash;123\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDurrant JD, McCammon JA (2011) Molecular dynamics simulations and drug discovery. BMC Biol 9:71\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee HS, Qi Y, Im W (2015) Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study. Sci Rep 5:8926\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFaraj SE, Gonz\u0026aacute;lez-Lebrero RM, Roman EA, Santos J (2016) Human Frataxin Folds Via an Intermediate State. Role of the C-Terminal Region. Sci Rep 6:20782\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIlyas U, Nazir B, Altaf R, Muhammad SA, Zafar H, Paiva-Santos AC et al (2022) Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives. Front Endocrinol 13:1022623\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharma P, Joshi T, Joshi T, Chandra S, Tamta S (2021) Molecular dynamics simulation for screening phytochemicals as α-amylase inhibitors from medicinal plants. J Biomol Struct Dynamics 39:6524\u0026ndash;6538\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChakravarty D, Guharoy M, Robert CH, Chakrabarti P, Janin J (2013) Reassessing buried surface areas in protein\u0026ndash;protein complexes. Protein Sci 22:1453\u0026ndash;1457\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChikalov I, Yao P, Moshkov M, Latombe J-C (2011) Learning probabilistic models of hydrogen bond stability from molecular dynamics simulation trajectories. BMC Bioinformatics 12:S34\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDutt M, Kumar A, Rout M, Dehury B, Martinez G, Ndishimye P et al (2023) Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA-dependent RNA polymerase using molecular modeling approach. J Cell Biochem 124:701\u0026ndash;715\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaisuradze GG, Liwo A, Scheraga HA (2010) Relation between Free Energy Landscapes of Proteins and Dynamics. J Chem Theory Comput 6:583\u0026ndash;595\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePrada-Gracia D, G\u0026oacute;mez-Garde\u0026ntilde;es J, Echenique P, Falo F (2009) Exploring the Free Energy Landscape: From Dynamics to Networks and Back. Levitt M, editor. PLoS Comput Biol. ;5:e1000415\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaidya AT, Kumar A, Kumar R, Darreh-Shori T (2022) Allosteric Binding Sites of Aβ Peptides on the Acetylcholine Synthesizing Enzyme ChAT as Deduced by In Silico Molecular Modeling. IJMS 23:6073\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUKumar S, Bithia R, TKumar D, Doss CGP, Zayed H (2022) Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach. J Biomol Struct Dynamics 40:1571\u0026ndash;1585\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGenheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449\u0026ndash;461\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHefti FF (2008) Requirements for a lead compound to become a clinical candidate. BMC Neurosci 9:S7\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePaul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al (2010) How to improve R\u0026amp;D productivity: the pharmaceutical industry\u0026rsquo;s grand challenge. Nat Rev Drug Discov 9:203\u0026ndash;214\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarrett JA, Yang W, Skolnik SM, Belliveau LM, Patros KM (2022) Discovery solubility measurement and assessment of small molecules with drug development in mind. Drug Discovery Today 27:1315\u0026ndash;1325\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuehlbacher M, Spitzer GM, Liedl KR, Kornhuber J (2011) Qualitative prediction of blood\u0026ndash;brain barrier permeability on a large and refined dataset. J Comput Aided Mol Des 25:1095\u0026ndash;1106\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBibi Z (2008) Role of cytochrome P450 in drug interactions. Nutr Metab (Lond) 5:27\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu C, Cheng F, Chen L, Du Z, Li W, Liu G et al (2012) In silico Prediction of Chemical Ames Mutagenicity. J Chem Inf Model 52:2840\u0026ndash;2847\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235\u0026ndash;249\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDoak BC, Over B, Giordanetto F, Kihlberg J (2014) Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chem Biol 21:1115\u0026ndash;1142\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNakai M, Fukui Y, Asami S, Toyoda-Ono Y, Iwashita T, Shibata H et al (2005) Inhibitory Effects of Oolong Tea Polyphenols on Pancreatic Lipase in Vitro. J Agric Food Chem 53:4593\u0026ndash;4598\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIvanov SA, Nomura K, Malfanov IL, Sklyar IV, Ptitsyn LR (2011) Isolation of a novel catechin from Bergenia rhizomes that has pronounced lipase-inhibiting and antioxidative properties. Fitoterapia 82:212\u0026ndash;218\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Tribhuvan University","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"HPL, secondary metabolites, molecular docking, MD simulations, DFT","lastPublishedDoi":"10.21203/rs.3.rs-5360869/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5360869/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Inhibiting human pancreatic lipase (EC3.1.1.3), a key enzyme in dietary fat breakdown and absorption, is an effective therapeutic approach for obesity control. Polyphenols, due to their multifaceted structure, enhance insulin sensitivity, reduce inflammation, and modulate gut microbiota, offering synergistic effects in controlling obesity.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods:\u003c/strong\u003e Considering the adverse side effects associated with current anti-obesity therapeutics, we explored a library of polyphenols known for their antiobesity properties to explicitly potent HPL inhibitors through extensive \u003cem\u003ein-silico\u003c/em\u003estudy including molecular docking, DFT, MD simulation, PCA, DCCM-based conformational analysis and pharmacokinetic analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults:\u003c/strong\u003e Significant binding affinity and interactions with catalytic triad (SER 152, HIS 263, and ASP 176) of HPL through molecular docking, alongside higher MM/GBSA values of -53.29, -52.76, and -53.37 kcal/mol, identified (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate), respectively, as potent leads. The DFT study and molecular dynamics simulation affirmed the strong reactivity of these compounds in the catalytic site of HPL and stable protein-ligand complex over 100 ns. FEL, PCA, and DCCM analysis also demonstrated these protein-ligand complexes' stable dynamic behavior and conformational changes. Moreover, post-simulation MMPBSA analysis indicated higher binding free energy and favorable ADMET and drug-likeness pharmacokinetic properties asserted these lead potentials as explicit HPL inhibitors with potential for obesity control.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e To sum up, (-)-epigallocatechin-3-O-p-coumarate, (+)-catechin-3-O-gallate, and (-)-epicatechin-3-O-(3'-O-methyl gallate) are identified as promising HPL inhibitors, with potential application in managing obesity due to their stable interaction with the enzyme and favorable pharmacokinetic characteristics.\u003c/p\u003e","manuscriptTitle":"Polyphenol Inhibition of Human Pancreatic Lipase: An In-Silico Study Towards Obesity Control","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-31 11:51:08","doi":"10.21203/rs.3.rs-5360869/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"41ff11f0-94bf-440f-8b29-4ad3bacb79dd","owner":[],"postedDate":"October 31st, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":39612727,"name":"Computational Biology"}],"tags":[],"updatedAt":"2024-10-31T11:51:09+00:00","versionOfRecord":[],"versionCreatedAt":"2024-10-31 11:51:08","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5360869","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5360869","identity":"rs-5360869","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}